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I.

Cast of Characters: The Bankruptcy Players

The Debtors
Insys Therapeutics, Inc. – Insys Therapeutics, Inc. a Delaware corporation, was the primary
debtor involved in this jointly administered set of bankruptcy cases.
Insys Subsidiary Companies: Insys Therapeutics, Inc. and the following subsidiaries
were substantively consolidated in these chapter 11 cases (collectively, “Insys”).
Insys Pharma, Inc.
IC Operations, LLC
Insys Development Company, Inc.
Insys Manufacturing, LLC
IPSC, LLC
IPT 355, LLC
Official Committee of Unsecured Creditors: The individuals were appointed by the U.S. Trustee
to represent creditors in the chapter 11 cases, (referred to as the “Creditors’ Committee”).
The Mckesson Corporation
Infirmary Health Hospitals, Inc.
Louisiana Health Service & Indemnity Co. d/b/a Blue Cross and Blue Shield of Louisiana
and HMO, LA, Inc.
Deborah Fuller, as administrator for the Estate of Sarah Fuller
Julie Key
James Starling, Jr.
Angela Mistrulli-Cantone
Lisa Mencucci

The Creditors’ Committee’s Professionals - The professionals acquired to assist the Creditors’
Committee relating to the chapter 11 cases.
Akin Gump Stauss Hauer & feld, LLP
Attorney
Province, Inc.
Financial Advisor
Bayard P.A.
Counsel in Delaware.
3

The Liquidation Trustee
William H. Henrich
Claims & Noticing Agent, Solicitation Agent
Epiq Corporate Restructuring, LLC
U.S. Trustee
Jane Leamy – Trial Attorney

Debtors’ Senior Management At Time of Filing:
Andrew G. Long
Chief Executive Officer and Director
Andrece Housley
Chief Financial Officer
Mark Nance
Chief Legal Officer and General Counsel
Venkat Goskonda, PhD
Chief Scientific Officer
Vikram Malhotra
Vice President of Corporate Development and Strategy
(Richard) Scott Warlick
Vice President of Manufacturing (Round Rock)
Danny Tuck, PhD
Senior Vice President of Quality Control
Eric Kizier
Vice President of Commercial
Ahmend Elkashef
Vice President of Clinical Development
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II.

Introduction

On June 10, 2019, Insys Therapeutics, Inc., and its subsidiaries (collectively, “Insys”), filed
a voluntary petition for relief under Chapter 11 of the Bankruptcy Code in the District of Delaware.
Insys jointly administered these chapter 11 cases pursuant to 1015(b) of the Federal Rules of
Bankruptcy Procedure. The chapter 11 bankruptcy ultimately led to a liquidation of the business’s
assets and Insys’s dissolution.
This document outlines how Insys navigated chapter 11 bankruptcy and the Opioid Crisis
that plagued the nation between 1999 and 2019. It further describes how the fraudulent marketing
and sale of Insys’s products led to the influx of litigation causing this chapter 11 bankruptcy case.
Further, it shows how a company like Insys, who at the time of filing had no funded debt and
approximately $37 million in cash equivalents and investments, found themselves hopelessly
insolvent and facing litigation, and left with no choice but to file for bankruptcy and wind up the
business in an orderly fashion.
III.

So Sweet you can Almost Taste it: Before Chapter 11 Bankruptcy
a. The Beginning of Insys Therapeutics, Inc.

In 1990, 48-year-old John N. Kapoor founded Insys Therapeutics, Inc., a specialty
pharmaceutical company that developed and sold certain drugs and drug delivery systems to
improve patients’ quality of life and address unmet patient needs.1 Kapoor was an Indian
immigrant and grew up in a family of modest means.2 For college, Kapoor moved to Mumbai and
graduated from the Institute of Chemical Technology with a degree in Pharmacy. 3 Kapoor then
graduated from the University at Buffalo with a degree in Medicinal Chemistry in 1972.4 As he
worked his way up in various pharmaceutical companies, Kapoor founded Insys Therapeutics,
Inc., which was incorporated in Delaware and based out of Chandler, Arizona.5
Insys Therapeutics, Inc. was the parent company of Insys Pharma, Inc. Insys Pharma was
the direct parent of the following subsidiaries: IPT 355, LLC, IC Operations, LLC, IPSC, LLC,
1

Declaration of Andrew G. Long in Support of Debtors’ Chapter 11 Petition and First Day Relief. Docket 11 at 3.

2

John N. Kapoor, Wikipedia (last edited Apr. 3, 2022), archived at Kapoor Wikipedia.

3

Id.

Barbara A. Byers, John N. Kapoor, PhD ’72, Uni. at Buff. (Mar. 28, 2011), archived at University at Buffalo;
Chidanand Rajghatta, Indian-American Pharma Executive Convicted of Opioid Racketeering, India Times, archived
at India Times.
4

5

Docket 11 at 6.
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and Insys Development Company, Inc., which was the parent company to Insys Manufacturing,
LLC.6 Insys’s corporate structure depicted in the chart below.

Each subsidiary had different day-to-day responsibilities. Insys Pharma, Inc. was a
subsidiary that dealt with pharmaceutical manufacturing.7 Insys Manufacturing, LLC took over
the manufacturing of the products.8 Insys Development Company, Inc., IPSC, LLC, and IC
Operations, LLC were shell corporations, which had few assets and were inactive in the business
operations.9 IPT 355, LLC’s operations remained unclear. On the Petition Date, Insys had 155
full-time employees, including 48 manufacturing employees, 38 sales and marketing employees,
34 research and development employees, and 35 administrative employees.10
b. The Products
In the day-to-day, Insys conducted research, including preclinical and clinical trials, they
manufactured, marketed, and sold their drugs and drug delivery systems to targeted therapies.11
These operations resulted in Insys’s two main products, Subsys and Syndros.
6

Docket 11 at 6.

7

Lexis Tool for Corporate Structures.

8

Id.

9

Id.

10

Docket 11 at 6.

11

Id. at 7.

6

Subsys was a sublingual liquid form of Fentanyl that reached the blood stream faster than
other normally administered drugs.12 Subsys was developed to relieve pain in cancer patients, as
it was fast-acting, alleviating pain within 5 minutes.13 On March 26, 2012, Insys launched Subsys
commercially, as the first fast-acting drug of its kind to be approved for cancer patients, by the
United States Food and Drug Administration (“FDA”).14 Syndros was an unconventional antinausea medication aimed to relieve symptoms for a range of ailments.15 Syndros was a liquid
dronabinol medication used to treat nausea caused by anti-cancer medications.16 Syndros was also
used to treat appetite loss and anorexia symptoms in people with AIDs.17 In July 2017, Syndros
launched as the first and only fast-acting medication of its kind approved by the FDA.18
Additionally, Insys began developing products called “Pipeline Products,” using similar
elements as those in Subsys and Syndros.19 Insys wanted Pipeline Products to be available, and to
provide better solutions for relief for patients suffering ‘life burdening’ conditions.20 For example,
Naloxone nasal spray was to be used to treat overdoses due to fentanyl, and Epinephrine Nasal
Spray was to be used to treat anaphylaxis.21 The Pipeline Products were to address unmet medical
needs, including pediatric epilepsy, weight-loss in cancer patients, and agitation in Alzheimer’s
disease, to name a few.22
Insys maintained two manufacturing facilities located in Round Rock, Texas, to develop
their products.23 These facilities were FDA inspected, and used well-established techniques to
12

Docket 11 at 7.

13

Id.; Sublingual – Dissolved under the tongue.

14

Id at 7-8.

15

Id. at 8.

Id.; Definition of Dronabinol - National Library of Medicine. “Dronabinol is used to treat nausea and vomiting
caused by chemotherapy in people who have already taken other medications to treat this type of nausea and vomiting
without good results.”
17
Id.
16

18

Id.

19

Id. at 8; Pipeline Products were products that Insys was working on at the time of filing. These products had not yet
been approved by the FDA.
20

Id.

21

Id. at 9.

22

Id. at 8.

23

Id. at 10.
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produce their dronabinol products.24 Similarly, as of March 5, 2019, Insys owned 94 worldwide
patents, and 62 pending patent applications, including 27 U.S. utility patents and 29 U.S. utility
patent applications.25 Their intellectual property portfolio enabled Insys to develop and market
their two main products, and to further develop their Pipeline Products.26 However, most of their
patents and applications were to expire between 2022 and 2029.27
c. Marketing & Sales
Insys sold products to wholesale pharmaceutical distributors, who then sold Insys’s
products to pharmacies, hospitals, and similar customers.28 Three wholesale pharmaceutical
distributors, AmerisourceBergen Corporation, McKesson Corporation, and Cardinal Health, Inc.,
individually comprised approximately 33%, 15%, and 10%, of Subsys’s and Syndros’ gross
sales.29 Additionally, Insys sold products to specialty retail pharmacies that directly sold products
to patients.30 Specialty retail pharmacies covered 39% of Subsys’s and Syndros’s gross sales.31
However, these sales appeared to be tainted with bribery and fraud.32
IV.

Down the Drain: Events Leading to Chapter 11

For a company with an extensive intellectual property portfolio, who created incredibly
popular products, and who, at the time of filing, had $37 Million in assets and no funded debt, how
did Insys’s resources dwindle so fast, forcing them to file for bankruptcy?33 There were two issues:
(1) internal fraud, and (2) an external public health crisis. Before 2019, claims against Insys came
from every direction: the legislature in Washington, D.C., patients across the nation, states, and
24

Docket 11 at 10.; See supra note 16, for more on dronabinol.

Id.; U.S. Patent and Trademark Office (USPTO) Definition of Utility Patent. - “Issued for the invention of a new
and useful process, machine, manufacture, or composition of matter, or a new and useful improvement thereof, it
generally permits its owner to exclude others from making, using, or selling the invention for a period of up to twenty
years from the date of patent application filing subject to the payment of maintenance fees.”
25

26

Id.

27

Id.

28

Id.

29

Id. at 10-11.

30

Id. at 10.

31

Id. at 11.

32

Gabrielle Emanuel, Pharmaceutical Executives Face Prison Time In Case Linked To Opioid Crisis, NPR (Jan. 13,
2020), archived at NPR Article.; See IV. b. External Factors: Fraud and Other Litigations.
33

Docket 11 at 11.
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even Insys’s executives. Litigation ensued and sales dropped: Insys presented all the symptoms
that indicated the need for a chapter 11 bankruptcy.
a. External Factors: The Opioid Crisis
In the early 2000s, the Opioid Crisis hit the U.S., and was a major event leading to Insys’s
destruction. The Opioid Crisis gained momentum in the late 1990’s, when health care providers
increasingly prescribed opioids because pharmaceutical companies reassured the medical
community that prescription opioid pain relievers were not addictive.34 By 2015, opioids were
prescribed approximately three times more than they were in 1999, even with prescriptions rates
decreasing between 2010 and 2015.35 However, there was no significant increase in chronic pain
in the U.S. that would justify the immense increase in prescription rates.36 In March 2016, the
Centers for Disease Control and Prevention (“CDC”) released the “Guideline for Prescribing
Opioids for Chronic Pains,” which reported changes in opioid prescriptions between 2006 and
2015, at a national level.37
According to the CDC’s report, more than 28,000 opioid overdoses were from prescription
opioids.38 On October 26, 2017, the Department of Health and Human Services declared a public
health emergency.39 Approximately 10.3 million people over the age of 12 misused opioids in
2018, and 9.9 million people specifically misused prescription pain relievers.40 Fentanyl, the key
product in Subsys, was one of the misused drugs.41 Fentanyl was approximately 50 times stronger

34

National Institute on Drug Abuse, Opioid Overdose Crisis, (archived on Apr. 24, 2022), archived at National
Institute on Drug Abuse.
35

Center for Disease Control and Prevention, Vital Signs: Changes in the Opioid Prescribing in the United States,
2006-2015, CDC (Jul. 7, 2017), archived at CDC: Vital Signs; National Conference of State Legislatures, Prescribing
policies: States Confront Opioid Overdose Epidemic (Jun 6, 2019), archived at Prescribing Policies.
36

Id.

37

Id.

38

Joey Garrison, Insys Therapeutics Founder John Kapoor to Served 66 Months in Prison for Opioid Scheme, USA
Today (Jan. 23, 2020), archived at USA Today.
39

Center for Medicare and Medicaid Services, Ongoing Emergencies and Disasters (last modified, Dec. 1, 2021),
archived at CMS.
40

Substance Abuse Mental Health Services Administration, Key Substance Use & Mental Health Indicators in the
United States: Results from the 2018 National Survey on Drug Use & Health (Aug. 2019), archived at SAMHSA, 9.
41

Id.; See in section IV. b.
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than heroin and up to 100 times stronger than morphine.42 In 2015, misuse and overdose were
great concerns, but the increased government intervention and monitoring led to a significant
decrease in opioid prescriptions, as depicted in the chart below.43

One study articulated, “annual high-dose opioid prescribing rates remained stable from
2006 to 2010, and then declined by 41.4% from 11.4 per 100 persons in 2010 to 6.7 in 2015,” just
3 years after Subsys hit the markets.44
Subsys sales were approximately 90% of Insys’s total revenue, but declined beginning in
2015. Insys claimed that the decline was caused by the nature of pricing increased on their
branded products, and the government and media attention on such product pricing.46 Subsys, and
other transmucosal immediate-release fentanyl (“TIRF”) products, experienced a “significant
downward trend” in the years before the Petition Date.47 Between 2015 and the Petition Date,
TIRF class prescriptions declined around 75%.48 All TIRF class prescriptions experienced a
decline at that time, but Insys claimed Subsys declined even faster than the overall market.49
45

42

USA Today.

43

CDC: Vital Signs.

44

Id.

45

Id.

46

Docket 11 at 23.

Id. at 22.; The Miami Herald: Transmucosal Definition & Meaning - Merriam-Webster: “Transmucosal: relating to,
being, or supplying a medication that enters through or across a mucous membrane (as of the mouth)
transmucosal fentanyl Noven Pharmaceuticals develops transdermal and transmucosal drug delivery systems and
technologies.”
47

48

Id. at 22-23.

49

Id. at 23.
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Overall, Insys experienced substantial operating losses—more than $200 million in 2017
and $100 million in 2018.50 Although Insys’s Pipeline Products were anticipated to generate
significant revenue in the future, Insys lacked sufficient liquidity to continue operations.51
Furthermore, Insys’s auditors failed to provide Insys with an ‘unqualified going concern audit
opinion’ for the Form 10-K, which was filed with the SEC in March, notwithstanding
management’s efforts to reduce costs and Insys’s bankers’ efforts to identify liquidity-enhancing
transactions.52 The going concern qualification negatively affected Insys’s attempts to obtain
funding.53 As if the significant revenue loss from the Opioid Crisis was not enough, Insys was
overdosed with internal complications.
b. Internal Factors: Fraud & Other Litigation
Since 2013, Insys claimed to have “faced an onslaught of investigative inquiries and
litigation claims by both the government and private parties in connection with the marketing of
Subsys,” some claims were common for all opioid manufacturers, but some were unique to Insys.54
Defending Insys at just one trial could amount to $10 million.55 The issues presented in the
lawsuits were mostly about the marketing and sales of Subsys, and the potential violations of the
Anti-Kickback Statute and the Food, Drug, & Cosmetic Act.56 Eventually, some of Insys’s
employees and executives were charged for crimes including conspiracy, bribery, mail fraud,
racketeering, and wire fraud.57
i. Enlisting Medical Professionals
John Kapoor directed Insys to implement “speaker programs,” which paid healthcare
professionals a large sum to advocate for Subsys prescriptions in presentations, regardless of how

50

Docket 11 at 23.

51

Id.

52

Id. at 24.

53

Id.

54

Id. at 12-13.

55

Id. at 12.

56

Id. at 13.

57

Gabrielle Emanuel and Katie Thomas, Top Executives of Insys, an Opioid Company, Are Found Guilty of
Racketeering, N.Y. Times (May 2, 2019), archived at NY Times.
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many people attended.58 The “speaker programs” allowed Insys to work around anti-kickback
laws that prohibited practitioners from earning an income from writing prescriptions.59 One doctor
admitted to being paid “speaker fees” even though he did not present on Insys’s behalf, similarly
stating that the presentation sign-up sheets were full of forged health care professionals’ names.60
Further, the doctor claimed that Insys encouraged him to write Subsys prescriptions by paying him
these “speaker fees.”61 Prosecutors proved that that doctor bullied patients into taking Subsys if
they pushed back.62
In October 2012, Kapoor instructed the Vice President of Marketing to determine whether
the speaker had a positive return on investment (“ROI”).63 An ROI is measured by dividing the
net return on the investment by the cost of the investment, multiplied by 100.64 No sources were
found directly discussing how the ROI’s were measured for such speaker programs, but the amount
the speaker received seemed to directly correlate with the number of prescriptions the speaker
wrote.65 The speakers were kicked out of the program if they did not have a positive ROI,.66 For
example, Insys targeted a physician’s assistant who practiced in a pain clinic in Somersworth, New
Hampshire, to promote their products at a “speaker program.”67 In 2012, Subsys’s first year on
the market, the physician’s assistant did not prescribe Subsys to any patients.68 However, in May
2013, the physician’s assistant joined the “speaker programs” because he knew he would be paid
‘kickbacks’ for writing Subsys prescriptions.69 When he joined, he received $44,000 in kickbacks
by writing approximately 672 Subsys prescriptions, many of which were unnecessary.70 Insys

58

Docket 11 at 13; Emanuel, supra note 31, at NPR Article.

59

Stacey A. Tovino, JD, PhD, Fraud, Abuse, and Opioids, 67 U. Kan. L. Rev. 901 (2019).

60

Id.

61

Id.

62

Id.

63

Press Release, The U.S. Attorney General Office, District of Massachusetts, Founder and Former Chairman of the
Board of Insys Therapeutics Sentences to 66 Months in Prison (Jan. 23, 2020), archived at District of MA.
64

Andrew Beattie, A Guide to Calculating Return on Investment (ROI), Investopedia.

65

Tovino, supra note 62, 901.

66

District of MA.

67

Id.

68

Id.

69

Id.

70

Id.; See also Tovino, supra note 62, 901.
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plead guilty to five counts of mail fraud for the “speaker programs,” which led to a deferred
prosecution agreement with the U.S. Attorney for the District of Massachusetts.71
Additionally, Insys created the “Insys Reimbursement Center,” another fraudulent
marketing tactic.72 After doctors wrote Subsys prescriptions, Insys called insurance companies
and fabricated patients’ stories to ensure the insurance would cover it.73 Without coverage, Subsys
medications were around $19,000 per month.74 Due to the high cost and substantial amount Insys
put into creating the drug, Insys misled insurers about patients’ diagnoses to obtain reimbursement
for Subsys prescriptions that had been written for Medicare and the Defense Health Agency
(“TRICARE,” discussed below) beneficiaries.75 A physician that wrote 1,283 prescriptions to
Medicare beneficiaries, amounting to more than 20% of Subsys’s prescriptions between 2009 and
2015, cost Medicare nearly $7 million.76 Kapoor not only approved the center’s business model,
but he demanded a 100% success rate, ensuring Subsys prescriptions were approved by insurance
companies, whether patient was qualified for it or not.77
ii. Fraud & Prosecutions
Insys’s severe and extensive fraudulent marketing behavior led to the prosecution of Insys
employees and physicians. For example, in 2017, an Alabama doctor linked to Kapoor’s case was
sentenced to 20 years in prison, and in 2019, a Michigan doctor was sentenced to 32 months in
prison for his involvement.78 On May 2, 2019, Kapoor and the four executives were convicted on
criminal racketeering charges in Boston’s federal district court, becoming the first drug company
executives to be convicted in the federal government’s fight to combat the opioid crisis.79 At the

71

Docket 11 at 13.

72

Id.

73

Id.

74

Id.

75

Press Release, Department of Justice, Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global
Resolution of Criminal and Civil Investigations, (Jun. 5, 2019), archived at DOJ Press Release.
76

Tovino, JD, supra note 62, 901.

77

FDA: Founder and Former Chairman of the Board of Insys Therapeutics sentenced to 66 Months in Prison.

78

USA Today.

79

Docket 11 at 21.
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time of the chapter 11 filing, Insys anticipated appeals, which would result in further litigation
expense.80
Only five days after agreeing to pay $225 million to the federal government for civil and
criminal claims for bribing doctors to prescribe Subsys, Insys filed for chapter 11 bankruptcy.81
Similarly, Insys had to pay millions in fees for the indemnification claims against former officers
and directors of Insys, who were defendants in two shareholder derivative lawsuits located in
Delaware and Arizona.82 Insys had paid these fees upfront, but was entitled to “claw-back” in the
amounts paid for individuals found liable.83
Insys claimed to address past management’s wrongdoings by taking steps to restructure
their executives and change their marketing practices to comply with state and federal laws and
regulations.84 Thus, Insys entered into a “Corporate Integrity Agreement and Conditional
Exclusion Release” with the Office of Inspector General for the U.S. Department of Health and
Human Services, where Insys promised to establish intensive programs promoting compliance
with statutes, regulations, and directives of the FDA, and of the Medicare, Medicaid, and other
federal health care programs.85 By entering into this agreement, Insys resolved one of the issues
of the U.S. Department of Health and Human Services.86
iii. Pending Actions
1) United States Government investigations & U.S. and State Qui Tam litigation
Between August 2013 and October 2016, under the qui tam provisions of the False Claims
Act, individuals called “Qui Tam Plaintiffs,” filed complaints against Insys regarding the

80

Docket 11 at 21.

81

Vanessa Romo, Insys Files for Chapter 11, Days After Landmark Opioid Settlement of $225 Million, NPR (Jun. 10,
2019), archived at NPR, Romo Article..
82

Docket 11 at 21.

83

Id. at 22.

84

Id. at 13.

85

Id. at 13-14.

86

Motion to Approve Compromise under Rule 9019 (Motion of Debtors Pursuant to 11 U.S.C. Section 105 and Fed.
R. Bankr. P. 9019 Authorizing and Approving Stipulation and Agreement Between the Debtors and the United
States. Docket 28 at 7.
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marketing and sales of Subsys.87 Except for attorneys’ fees and retaliation claims, these Qui Tam
Plaintiffs’ actions were dismissed with prejudice, and the U.S. Department of Justice (“DOJ”)
commenced civil and criminal actions against Insys (“DOJ Civil Action” and the “DOJ Criminal
Actions,” collectively, the “DOJ Actions”).88 The DOJ filed DOJ Civil Actions on behalf of the
U.S. Department of Health and Human Services, the Centers for Medicare and Medicaid Services,
and TRICARE.89
The government intervened in five of the “qui tam” lawsuits, accusing Insys of violating
the Civil False Claims Act.90 The U.S. alleged that Insys paid kickbacks to persuade physicians
and nurse practitioners to prescribe Subsys for their patients, covering up the kickbacks with
“speaker program” payments and “jobs for the prescribers’ relatives and friends, and lavish meals
and entertainment.”91 Further alleging that Insys improperly influenced physicians to prescribe
Subsys for patients who did not have cancer.92 Insys’s fraudulent schemes caused tragic results,
for example, a woman named Sarah died from a Subsys overdose after being improperly prescribed
it for pain from a car accident.93 In an interview, Sarah’s mother said she had no idea the FDA
had only approved Subsys for terminal cancer patients who developed a tolerance for other
painkillers, stating that Sarah was not similarly qualified.94
On August 8, 2018, Insys entered into an agreement with the DOJ, to resolve the DOJ
Actions.95 Here, Insys agreed to pay a minimum liability exposure of $150 million over five years,
with the potential for additional contingency-based payments, up to $75 million, that were
associated with certain events.96 This agreement caused Insys’s funds to deplete significantly, and
87

Docket 28 at 15; see 31 U.S.C. § 3730(b). Qui Tam refers to the whistleblower provisions of the False Claims Act,
permitting citizens to bring suit on behalf of the U.S. for false claims and share in any recovery from the suit.
88

Docket 11 at 15.

89

Id.

90

DOJ Press Release. The lawsuits: United States, et al., ex rel. Guzman v. Insys Therapeutics, Inc., et al., 13-cv5861; United States ex rel. Andersson v. Insys Therapeutics, Inc., 14-cv-9179; United States ex rel. John Doe and
ABC, LLC v. Insys Therapeutics, Inc., et al., 14-cv-3488; United States ex rel. Erickson and Lueken v. Insys
Therapeutics, Inc., 16-cv-2956; and United States ex rel. Jane Doe, et al. v. Insys Therapeutics, et al., 16-cv-7937.
91

Docket 11 at 15; DOJ Press Release.

92

Id.

93

USA Today; Joe Eaton, How Drugmaker Bribed Doctors and Helped Fuel the Opioid Epidemic, AARP (Jan. 24,
2020), archived at AARP Article.
94

AARP Article.

95

Docket 11 at 16.
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at this time, Insys knew they were no longer able to pay the amounts the DOJ sought.97 After
months of negotiations, Insys and the DOJ entered into several interrelated documents, finally
reaching a settlement (the “DOJ Settlement”).98 However, to ensure that the sales were approved
without major litigation, and to allow Insys to maximize value for their assets, the DOJ settlement
did not carry over to any purchasers of Insys’s assets.99 The DOJ Settlement included (1) a
settlement agreement with the U.S. which resolved the DOJ Civil Action; (2) the “Corporate
Integrity Agreement and Conditional Exclusion Release” mentioned above; (3) a plea agreement
between Insys and the DOJ; and (4) the related deferred prosecution agreement.100
On June 5, 2019, Insys entered into the DOJ prepetition civil settlement, requiring Insys to
make settlement payments over time to the U.S., which resolved the DOJ Civil Action, and
released any remaining U.S. claims against Insys.101 According to the DOJ prepetition civil
settlement, and approval of the Court, Insys promised the DOJ an unsecured claim in the Chapter
11 cases of $243 million, although the DOJ’s recovery was capped at $195 million, which included
$5 million prepetition payments.102 If Insys failed to fulfill their obligations under the agreement,
the U.S. was provided an “undisputed, non-contingent, liquidated allowed claim,” against Insys
for damages under the False Claims Act that were for $600 million and penalties.103 Further, the
DOJ prepetition civil settlement stated that Insys would enter the DOJ Criminal Resolution and
the deferred prosecution agreement.104
On June 7, 2019, pursuant to the DOJ Criminal Resolution, Insys Pharma, Inc. plead guilty
to five counts of mail fraud, agreeing to pay a $2 million fine and $28 million in forfeiture with $5
million due ten days after July 10, 2019, when Insys Pharma, Inc. was set for sentencing.105 Under
the deferred prosecution agreement, the U.S. agreed to defer prosecution against Insys for five
96

Docket 11 at 16.; Docket 28 at 6: a minimum liability exposure of $150 million means that Insys had to pay a
minimum of $150 million, although that the DOJ Settlements could have required an additional $75 million.
97

Docket 28 at 7.

98

Id.

99

Id. at 13.

100

Id. at 7.

101

Id. at 10.

102

Docket 11 at 16-17.; The $243 million was a non-priority, general unsecured claim.

103

Docket 28 at 11.

104

Id.

105

Id. at 17.
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years for its criminal fraud actions, if Insys satisfied the deferred prosecution agreement, and
further agreed that Insys was jointly and severally liable for money owed by Insys Pharma under
the DOJ Criminal Resolution.106
2) State & Municipality Litigations
Additionally, Insys received information requests or subpoenas from at least 15 states’
offices of the Attorney General (“the AG Investigations”), including: Municipal Actions, brought
in approximately 32 states, in state and federal courts, which named Insys as defendants in
approximately 1,000 cases, the majority of which were consolidated into Multidistrict Litigation
No. 2804 (the “MDL”), brought in the U.S. District Court for the Northern District of Ohio, as
well as approximately 230 Municipal actions pending outside the MDL (“Non-MDL”).107
3) Private Insurance Provider & Personal Injury Plaintiff Litigation
Internal fraud litigation was not the only issue that drained Insys’s cash, as of the Petition
Date, claims were brought by, or on behalf of, six insurance companies and seven self-funded
health care plans.108 Additionally, 28 personal injury lawsuits were brought, including those that
sought class action status.109 The claims ranged from negligent misrepresentation and wrongful
death to fraud regarding Insys’s marketing and sale of Subsys.110
c. It’s Time for Bankruptcy
The Opioid Crisis litigation; the litigation of Insys’s executives; and Insys’s business
structure, caused Insys’s revenue to disappear down the drain. After experiencing the Seeing the
deterioration of their financial status, Insys implemented procedures to reduce costs, hoping to
reduce their spending to mirror the decrease in revenue.111 Before filing, on July 12, 2018, Insys
eliminated 45 positions, including 30 employees from marketing and sales, representing
approximately 9% of Insys’s workforce at that time.112 Less than six months later, Insys eliminated
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48 more positions, including 36 employees, and a majority from in marketing and sales,
representing approximately 13% of the workforce at that time.113 On May 31, 2019, Insys
eliminated an additional 8 positions, representing 5% of their workforce at that time.114
i.

JMP Securities Review

On November 5, 2018, Insys hired JMP Securities, LLC (“JMP”) in hopes of enhancing
liquidity by having JMP review strategic alternatives for their opioid-related assets, including
Subsys.115 Unfortunately, even after JMP’s help which lead to several offers for Subsys, the
proposed transactions could not be consummated fast enough to ‘fund the gap’ between their
existing cash-burn situation, and the time in the future where they expected to generate revenues.116
As the draining of Insys’s revenues continued without replacement, Insys employed Lazard Freres
& Co. LLC (“Lazard”) to advise Insys on capital planning and strategy alternatives to help with
Insys’s opioid related assets, and to explore other potential opportunities for a sale or similar.117
Insys gave Lazard free-range, but was ultimately unable to identify a transaction or group of
transactions sufficient to ensure the Insys’s long-term survival.118
ii.

Changing Management

As of April 2017, Insys replaced half of the independent directors on their Board, as well
as several senior management positions, including CEO, CFO, and vice presidents of Commercial,
Sales, Human Resources, and Clinical Development.119 On October 29, 2017, Kapoor resigned
on and placed his outstanding shares of common stock, approximately 59% of Insys, into an
independent trust.120 On April 15, 2019, Andrew Long was appointed CEO; Andrece Housley
who served as Insys’s Corporate Controller, as CFO; and Dr. Venkat Goskonda, who served as
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Insys’s Senior Vice President of Research and Development, as new Chief Scientific Officer.121
As a result, a majority of Insys management team was new to the company since 2015.122
iii.

Insys’s Three-Step Chapter 11 Process

Finally, Insys decided that their liquidity situation, combined with the substantial litigation
they faced, meant that a chapter 11 bankruptcy was their only way out.123 Insys’s entered chapter
11 bankruptcy with the goal to maximize value for all of their stakeholders.124 Insys further
believed that the chapter 11 filing provided them the ability to negotiate a “consensual resolution
with some or most of their creditor groups, as they did with the DOJ.”125
Insys’s their three-step chapter 11 was as follows: (1) Insys planned to pursue affirmative
claims to maximize revenue, including recovery of indemnification claims, as discusses above,
and filing claims against insurance carriers who Insys believed wrongly denied them coverage in
years before the Petition Date; (2) Insys needed to “stop the bleed” on litigation-related legal
expenses and needed the automatic stay of Bankruptcy Code section 362.126 Additionally, Insys
planned to seek an injunction against the majority of the litigation proceedings that were not stayed
by section 362 due to the “police powers” exception to the automatic stay; (3) Insys planned to
quickly create a chapter 11 plan and make distributions as soon as possible by requesting the Court,
pursuant to section Bankruptcy Code section 502(c), to adopt estimation procedures and estimate
Insys’s “aggregate liability with respect to certain categories of claims related to Subsys to avoid
undue delay of the administration the chapter 11 cases.”127
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d. The Voluntary Petition
Insys first filed their voluntary petition for chapter 11 bankruptcy under Insys Therapeutics,
Inc.
At the time of the petition, Insys claimed to have between 5,001 and 10,000 creditors.129
On the Petition Date, CEO Andrew Long provided information about the company’s operations.130
Insys’s total assets amounted to $175,114,056, and their total debts were $262,504,755.131
Additionally, Insys represented John N. Kapoor, and Insys Pharma, as well as the entities under
Insys Pharma.132
128

V.

First Day Motions

On the Petition Date, Insys filed a multitude of “First Day Motions.” These motions were
naturally divided into three main subsections: (1) administrative motions, (2) motions to maintain
day-to-day operations, and (3) Prepetition Motions.
a. Declaration of C.E.O. Long in Support of Insys’s Petition & First Day Relief
Along with the voluntary petition, Andrew G. Long (“Long”), the CEO at the time of the
petition filed a declaration in support and was evidentiary support for all first day motions. Long’s
declaration clarified, to other parties and the Court, the events and circumstances that compelled
Insys to file for chapter 11 bankruptcy.133 Long explained why he had the ability to shed light on
day-to-day operation, business financial affairs, and the goals Insys had for filing for chapter 11
bankruptcy.134
1. Part One: Administrative Motions
The first category of first day motions was Administrative motions. Administrative
motions requested the Court to approve the administrative procedures Insys proposed for the
chapter 11 cases.
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a. Motion for Joint Administration
First, Insys filed was the motion for joint administration.135 Insys requested joint
administration under the Federal Rules of Bankruptcy Procedure Rule 1015(b) (“Bankruptcy
Rules”), and the Rule 1015-1 of the Local Rules of Bankruptcy Practice and Procedure of the
United States Bankruptcy Court for the District of Delaware (“Local Rules”).136 Insys asked the
Court to grant them joint administration over all of their entities for procedural purposes in these
chapter 11 cases.137
Bankruptcy Rule 1015(b) states that if “two or more petitions are pending in the same court
by or against … a debtor and an affiliate, the court may order a joint administration of the
estates.”138 If Insys filed the motion under Bankruptcy Rule 1015, the Local Rule 1015-1 provided
Insys the right to request an order “without notice or hearing.”139 Under Bankruptcy Rule 1015(b),
Insys had the right to joint administration so long as their assertion was supported by an “affidavit,
declaration, or verification,” to establish proper joint administration of multiple claims and proof
that the Court would be put at ease of the administrative burden.140 As provided above, Long filed
a declaration, which supported this motion for joint administration.141 Additionally, Insys asserted
that approving this motion would neither affect them adversely, nor would it have consolidated
the affiliates estates, and that any creditor could file a claim against an individual affiliate, or its
estates, regardless of this motion’s approval.142
On June 11, 2019, the Court granted Insys joint administration for procedural purposes
only.
The Court required Insys to file a document directing procedural consolidation and joint
143
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administration of the following: Insys Therapeutics, Inc.; IC Operations, LLC; Insys Development
Company, Inc.; Insys Manufacturing, LLC; Insys Pharma, Inc.; IPSC, LLC; and IPT 355, LLC.144
b. Application for Authority to Appoint EPIQ as Claims and Noticing Agent
Next, under sections section 156(c) of title 28 of the Unite States Code, section 105(a) of
the United States Code (the “Bankruptcy Code”), and Rule 2002-1(f) of the Local Rules, Insys
requested the Court approve the appointment of EPIQ Corporate Restructuring, LLC (“EPIQ”) as
their claims and noticing agent.145 Insys stated that EPIQ may have done work outside the work
permitted by section 156(c), and therefore Insys requested EPIQ to be their administrative advisor
pursuant to Bankruptcy Code section 327(a).146 Section 156(c) requires Insys to obtain and review
engagement proposals from at least two other court-approved claims and noticing agents, ensuring
that the selection process was competitive.147 Insys asserted that EPIQ was competitive and
reasonable given the quality-of-service they provided.148
Local Rule 2002-1 provides that “in all cases with more than 200 creditors or parties in
interest on the creditors list, the debtors shall file [an application to authorize the retention of a
noticing or claims clerk], unless the court orders otherwise…. The notice and/or claims clerk shall
comply with the Claims Agent Protocol.”149 Thus, Insys asserted Local Rule 2002-1 was satisfied
due to their anticipation of more than 5,000 entities to be notice during their chapter 11 cases.150
Additionally, Insys claimed that the only request in this motion was for EPIQ’s work under
Bankruptcy Code section 156(c), and Local Rule section 2002-1.151 Under Bankruptcy Code
sections 156(c) and 503(b)(1)(A), Insys requested EPIQ to be treated as an administrative expense
of their chapter 11 estate.152 Further, Insys requested that EPIQ be paid in the ordinary course of
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business without further application of the Court.153 EPIQ agreed to maintain records of their
services showing the dates, categories of services, charges and expenses, and to serve this data
monthly to various parties, and to those who requested it.154 Insys proposed to pay a retainer of
$25,000 to EPIQ, which EPIQ sought to apply to all prepetition invoices and to replenish the funds
after such application, agreeing that the retainer would be held as security for payments incurred
for their services.155 Thus, Insys asserted all requirements under Bankruptcy Code section 156(c)
had been satisfied.156
On June 11, 2019, the Court authorized Insys to retain EPIQ as claims and noticing
agent. The Court also authorized and directed EPIQ to perform noticing services and to receive,
maintain, record, and otherwise administer proofs of claim filed in the chapter 11 cases; and
maintain both official claims registered to each affiliate, to provide public access to every proof of
claim unless the court stated otherwise, and to provide the clerk with certified duplicates of the
proofs of claims.158
157

c. Motion for Interim & Final Orders to Establish Noticing Procedures & to Approve
Restrictions on Certain Transfers of Worthless stock
Insys requested the authority to establish procedures to protect Insys’s consolidated net
operating loss carryforwards (“NOLs”) and certain other tax benefits (collectively, “Tax
Attributes”).159 Insys asserted the procedures would apply to their common stock; and other
similar options or rights to acquire common stock; and any claim of worthless stock deduction
under 165(g) of title 26 of the United States Code (the “Tax Code”) with respect to common stock
by a majority stockholder.160
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i.

Automatic Stay Bars Any Equity Transfer that Would Diminish or Limit Insys’s
Interest in Tax Attributes

Additionally, Insys sought authority to monitor and approve certain changes in the
beneficial ownership of common stock, and certain worthless stock deduction claims, to protect
against ownership change during the chapter 11 cases, which would preserve the potential value
of the Tax Attributes.161 Bankruptcy Code section 362 enjoins all entities from taking action to
obtain possession of property of, or from the estate, or to exercise control over property of estate.162
Bankruptcy Code section 541 states that ‘property of the estate’ includes “all legal or equitable
interests of a debtor in property as these chapter 11 cases commence, this includes tax benefits.”163
Insys asserted that Tax Attributes were valuable to their estates, therefore protected by the
automatic stay against the actions that diminished or eliminated the value, including voluntary and
involuntary transfers and tax deduction claims, resulting in ownership change.164 Similarly,
Bankruptcy Code section 363(a)(3) allowed the automatic stay to enjoin actions that would
adversely affect Insys’s ability to use NOLS and other tax benefits.165
ii.

The Procedures were Necessary & in the Best Interest of Insys, Their Estates, and
Their Creditors

Insys claimed that the proposed procedures would help their ability to seek necessary relief,
if any transfer or claim appeared to potentially harm Insys’s ability to utilize their Tax
Attributed.166 Insys wanted to utilize the Tax Attributes to offset a substantial portion of any gain
that would have surfaced upon sale of appreciated assets during the chapter 11 cases.167 Insys
further claimed that if ownership change occurred, it could have limited the use of Tax
Attributions, therefore, reducing the after-tax proceeds that would have been available to satisfy
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the creditor’s claims.168 Thus, Insys requested the relief subject to Bankruptcy Rule 3001(e) and
other laws.169
Tax Code section 382(l)(6) provides that, if a debtor undergoes ownership change, and
382(l)(5) does not apply, then, for purposes of calculating the annual limitation under that section,
the appropriate value of the debtors shall reflect an increase in value of the debtors resulting from
any surrender or cancellation of the creditors’ claims.170 Thus, Insys stated that the Court should
grant the requested relief to prevent ownership change prior to the date of the plan, or any
applicable order.171
On June 11, 2019, the Court entered an interim order granting all of Insys’s requests in this
motion.172 Finally, on July 3, 2019, the Court issued a final order granting Insys’s requests on a
final basis.173
d. Motion for the Authority to Pay Certain Prepetition Wages & Employee Expenses
Next, Insys requested: (i) the authority, and the sole discretion, to pay and honor certain
prepetition claims and obligations relating to business programs for their employees, including (a)
unpaid wages and taxes; (b) pay for supplemental workforces; (c) reimbursable expenses; (d) the
Amex Program; (e) employee benefits programs; (f) the severance program; (g) the 401K saving
plan; and (h) other programs; and (ii) other related relief.174
i.

Payment of Employee Obligations

First, under Bankruptcy Code section 363(b) Insys requested the authority to pay
prepetition employee obligations.175 363(b)(1) provides that “after notice and hearing, [the debtor]
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may use, sell, or lease other than in the ordinary course of business, property of the estate.”176
Thus, Insys claimed that the Court could authorize Insys to pay prepetition claims that have a
“sound business purpose for doing so.”177 Pursuant to Bankruptcy Code section 105(c), the Court
has the authority to authorize relief requested because the relief was necessary for Insys to continue
their fiduciary duties under Bankruptcy Code 1107(a).178 1107(a) provides an implied duty for a
debtor to protect the estate, including an operating business’ ongoing-concern value for the debtor
and the other interested parties.179 Insys asserted that they should be afforded this authority to
because employees would have to move on if they were not being paid.180 Similarly, Insys claimed
it was necessary to keep employees so they could maintain customer relations and satisfy customer
obligations.181
ii.

Payment of Certain Employee Obligations Required by Law

Insys requested the authority to remit deductions and payroll taxes to the appropriate
entities, including the employee earnings that the employees and governments designated on the
employee’s paychecks.182 Bankruptcy Code section 541(b) states that funds on hand relating to
certain deductions were not Insys’s property, including contributions to employee benefit
programs, child support and alimony payments that were withheld from the employee’s paycheck
including trust fund payroll taxes.183 Insys asserted that these deductions and taxes were not their
property, therefore requesting the authority to remit these amounts to the proper parties in the
ordinary course of business.184
iii.

Severance Payments that were Outside of those Under Bankruptcy Code §503(c)

Lastly, Insys requested authority to pay employees who were terminated after the petition
date, and to honor obligations in the ordinary course of business, except those that were outside of
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Bankruptcy Code section 503(c).185 Insys claimed 503(c) was not relevant to severance payments
because such payments were in the ordinary course of business.186 Insys asserted that the Court
could approve this request, if the severance program satisfied requirements under Bankruptcy
Code section 363(b).187 Similarly, courts within the jurisdiction have held severance payments
can continue so long as they were in the ordinary course of business, to employees terminated
post-petition.188 Under 363(b), Insys asserted that they had a “sound business purpose” for
continuing to pay severance to employees terminated post-petition because retaining employees
was critical, and severance pay would incentivize other employees to honor their prepetition
obligations.189
iv.

Objections and Orders

On June 11, 2019, the Court entered an Interim order, granting Insys’s requests.190 Further,
the Court authorized Insys to pay the amounts payable as of the Petition Date, and those available
in the Interim Period, which were not to exceed $733,120.191 Similarly, salaries and sick leave by
a single employee were not to exceed $13,650, and Insys could not pay bonus commission, unless
provided otherwise.192 On July 3,2019, the Court granted the motion on a final basis.193 The Court
filed an amended final order on that same day adding in the Employee Bonus Programs to be paid
after initially leaving them out.194
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On August 19, 2019, Insys filed a statement in support of the post-petition severance
program and honoring obligations.195 Insys stated that employees were to be paid severance in the
ordinary course of business for events including job elimination, change in management, or
reorganization.196 Similarly, Insys clarified eligible employees included those who had an
employment agreement with Insys, who entered into a separation agreement with them, or where
the eligible employee is otherwise entitled to such benefit by law.197 Further, Insys stated that
severance payments were to be made to key employees who were winding up their affairs and
post-sale business.198 Key employees were to receive up to 8 weeks of severance pay, and the
aggregate payment was not to exceed over $500,000.199 Insys then stated that no party in interest
had objected to the terms of the Prepetition Severance Program, and the response deadline
involving wages was only extended for the Creditors’ Committee.200
On August 20, 2019, the Creditors Committee filed a limited objection and statement in
opposition to this motion.201 Various parties filed a joinder to the statement and limited objections,
including Non-MDL Municipal Plaintiffs (Jason Gibson),202 Florida,203 Non-MDL Municipal
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Plaintiffs (Michael Busenkell),204 the Minnesota Board of Pharmacy,205 New York,206 New
Jersey,207 Non-MDL Municipal Plaintiffs (William Hazeltine),208 and Arizona.209 Finally, on
September 19, 2019, the Court rendered the final order after reviewing all the objections, the
Severance plan, and having held a hearing to consider the request on August 22, 2019.210 The
Court denied the motion at the hearing with a motion to adjourn sine die, with direction for Insys
and the Creditors’ Committee to develop a protocol for determining the eligible employee.211
When Insys and the Creditors’ Committee agreed to such protocol, the Court had a final
hearing on severance on September 19, 2019, and granted the motion. 212 The Court authorized
Insys to act in accordance with only the severance plan and the severance eligibility Protocols,
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further authorizing Insys to pay and honor all stated obligations within the order.213 The Court
specified that Insys could make payments up to the aggregate of $500,000, and that all payments
were to be made to those specified by the severance eligibility protocol, as well as the Non-insider
Eligible Employees identified by Insys as “Severance Program Participants.”214 The Court
required Insys to file their severance program participant list within 10 business days of making
such list, setting forth the name, title, annual base salary, and severance payment of each name
listed.215 Within 10 days of making the payments, Insys was required to send a notice to all
Severance Notice Parties and the U.S. Trustee with an unredacted schedule of payments.216
e. Motion for Authority to Establish Important Deadlines
Insys filed another motion requesting the authority: (i) to establish deadlines for filing
proofs of claim; (ii) to establish the form and manner of the notice there of; and (iii) to approve
Insys’s plan for providing notice of Bar Dates and other important deadlines.217
i.

Procedure for Filing Proof of Claims

Insys requested for their proposed procedures to be approved for filing proofs of claims.218
Under Bankruptcy Rule 3003(c)(2), any creditor whose claim is not scheduled or is scheduled as
disputed, contingent, or unliquidated that, fails to file a proof of claim by the applicable bar date,
could not be treated as a creditor for voting and distribution purposes.219 Thus, Insys requested
that any holder of a claim required to file a claim of proof under the proposed order, but that failed
to do so on, or before the specified bar date, were to not be treated as a creditor for voting or
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distribution rights during these chapter 11 cases.220 On July 15, 2019, the Court granted Insys’s
plan for how to file the proof of claims.221
ii.

The Proposed Bar Dates and Mailing Procedures

Insys requested the Court’s approval of their proposed bar dates, including general bar
dates, government bar dates, and administrative claim bar dates.222 Under Bankruptcy Rule
2002(a)(7), and to provide sufficient notice to all interested parties, Insys proposed to serve the
following documents, to all parties listed on the proposal, at least 30 days prior to the general bar
date, via first-class mail: (1) proof of claims form and (2) the general bar date notice.223 This
deadline included all claimants who would file a proofs of claim including secured claims,
unsecured priority claims, unsecured non-priority claims, and all claims arising under Bankruptcy
Code section 503(B)(9) against all of Insys’s affiliates.224 Additionally, EPIQ, as noticing agent,
were to receive the proofs of claim before, or on the general bar date, unless the person or entity’s
claim fell within one of the exceptions in the motion.225
Bankruptcy Code section 502(b)(9) states that a government claim “shall be timely filed if
it is filed before 180 days after the date of the order for relief or such later time as the Bankruptcy
Rules may provide.”226 Insys requested that the Court establish the governmental bar date to be
December 9, 2018.227 Section 503(a) provides that an entity may file a timely request for “payment
of administrative expenses or may tardily file such request if permitted by the court for cause.”228
Insys requested the Court to establish that the administrative claim’s bar date be October 24,
2019.229 On July 15, 2019, the Court approved Insys’s request to establish the general bar date
and how to give notice to the parties about the established general bar date.230
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iii.

Publication of the Notice of Commencement & Supplement Notice Plan

Insys requested the Court to approve their plan of publication of notice, and the supplement
notice plan.231 Insys stated notice would be provided to all parties at least 30 days prior to requested
the general bar date.232 That gave EPIQ three business days from filing Insys’s schedules and
statements to mail the general bar date notice.233 Bankruptcy Rule 2002(a)(7) requires a debtor
provide at least 21 days’ notice prior to the time of filing proof of claims, and Rule 2002(p)(2)
states creditors with foreign addresses be given at least 30 days.234 Similarly, “where a creditor is
unknown to the debtor, due process requires only that the debtor take reasonable steps, such as
notice by publication, to provide constructive notice of the deadline of proof of claims.”235
On July 15, 2019, the Court granted Insys’s motion and set the proposed notice date, stating
notice must be provided “as soon as practicable, but in no event later than 30 days prior to the
General bar date.”236 Additionally, the Court required Insys to post, with any modifications, once
in a national edition of the New York Times and USA Today, and in ten other local news sources at
Insys’s and the Creditors’ Committee’s discretion.237 The Court stated that the requirements above
were satisfied giving constructive notice to unknown creditors.238
f. Motion to Extend Time to File Schedules of Assets & Liabilities & Statements of
Financial Affairs
Insys requested an extension of 21 days to the initial 28-day period to file their schedules
and assets and liabilities and statements of financial affairs, allowing the Insys a total of 49 days
after the Petition Date to file their schedules and statements.239
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i.

The Rules

Bankruptcy Code section 521 requires a debtor to file schedules of assets and liability, as
well as statements of financial affairs, unless the Court specifies otherwise.240 Bankruptcy Rule
1007(c) states that schedules and statements must be filed within 14 days after the petition date
unless the court grants an extension.241 However, in a voluntary chapter 11 case with over 200
creditors, and that otherwise satisfies requirements of Local Rule 1007-2, the debtor is allotted 28
days after the Petition Date to file the schedules and statements.242
ii. Insys’s Request
Insys claimed an extension for filing the schedules and statements was a necessity that due
to the complexity of their case, which identified more than 200 creditors, as well as the limited
time and resources available they had to get the required information.243 Similarly, Insys claimed
that those responsible for obtaining this information had other day-to-day operational tasks, and
forcing them to act within such a time constraint was too burdensome.244 Further, Insys claimed
that creditors and parties in interest were not prejudiced or adversely affected by the extension.245
18 days after filing the motion, the Court granted Insys’s motion for the full 21-day request,
allotting Insys 49 days to prepare and file its schedules and statements.246
g. Motion to Approve Compromise Under Rule 9019 of the Bankruptcy Code
Insys requested the Court to give them authority and the approval of stipulations and
agreements between Insys and the U.S., discussed above.247 Prior to filing, Insys entered into
several agreements with the U.S. and other federal agencies that resolved some of “the federal
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government’s criminal, civil, and administrative actions against them.”248 Insys filed this motion
hoping to constitute their final agreement with the DOJ.249
Insys claimed that approving the agreement with the DOJ was in all interested parties’ best
interests because it allowed Insys to resolve their most significant liability for “a fraction of the
total amount asserted by the DOJ,” and “significantly less than the amount the federal government
represented,” and by “removing the threat of governmental action against them,” they maximized
the proceeds Insys could receive from a sale, and placed the burden of their biggest claim behind
them, which would enable Insys to focus on the other creditors’ and negotiating with them.250
On July 1, 2019, Florida filed a limited objection to the motion to approve the compromise,
but did not object to the majority of the terms in the proposed agreement.251 Florida stated that
Insys unjustly provided the U.S. with unequal treatment regarding similarly situated creditors by
providing the U.S. with a substantial ‘Allowed Claim’ that could not be subordinated.252 Finally,
Florida stated that if the Court approve this motion, Florida requested for the Court to specify that
third parties were not bound by the provisions waiving chapter 5 claims. 253 On October 7, 2019,
the Court authorized and approved the stipulation and agreement that granted Florida’s requests.254
h. Declaration in Support of Insys’s Motion for Preliminary Injunction
After filing the motion for preliminary injunction and motion for entry of an order
establishing procedures and scheduling for estimation, Insys filed CEO Andrew Long’s
declaration in support.255 Long reiterated that Insys was defendant to approximately 1,000 lawsuits
related to Subsys and how these suits took a significant toll on Insys’s already limited financial
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resources.256 Further, Long pointed out the amount of time continuing litigation would have
required, which would have distracted Long and other senior management from maximizing value
for these chapter 11 proceedings.257 For this reason, Long submitted his declaration in support of
Insys’s motion for preliminary injunction and their motion for entry Insys’s Estimation Motion.
2. Part Two: Day to Day Operations
Motions relating to day-to-day operations were filed to request permission from the Court
to continue procedures that enabled Insys to continue to work through the chapter 11 cases.
a. Motion to Continue Cash Management
First Insys filed the motion to continue existing cash management. The cash management
system provided Insys benefits, including the ability to control corporate funds, ensuring the
maximum availability of funds when and where necessary, and it reduced costs and administrative
expenses by allowing Insys to move funds, and to develop a timelier, more accurate account
information.258 Bankruptcy Code section 363(c)(1) of authorizes a debtor to “use property of the
estate in the ordinary course of business without notice or hearing.”259 At the time of the petition
date, Insys’ cash management system was composed of thirty-three different bank accounts.260
Before the petition date, in April 2019, Insys began transferring their accounts from
JPMorgan to Western Alliance.261 Insys’s accountants regularly maintained these accounts.
because, although they were mostly automated, the system required various levels of
authorizations to release disbursement.262 Insys claimed maintaining the cash management system
was critical to ensure that Insys could seamlessly continue transactions and collect revenue.263
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On June 11, 2019, the Court granted Insys’ request on an interim basis.264 Under
Bankruptcy Code section 363, the Court authorized Insys request to continue using and managing
their cash management system, to collect and disburse cash in accordance with the system, and to
make changes in the ordinary course of business.265 Finally, on July 5, 2019, the Court granted
Insys’s request on a final basis.266
i. Authority to Continue Performance of Intercompany Transactions & to be
Accorded to as Administrative Expenses
Next, Insys requested authority to continue performance of Intercompany Transactions,
requesting “administrative expense priority” on post-petition intercompany claims.267
Intercompany transactions were money transfers made from one Insys subsidiary to another.268 A
general ledger required all entities to be balanced at the legal entity level, meaning when the system
entered in an intercompany receivable on one entity’s balance sheet, it automatically created a
corresponding intercompany payable on the affiliate’s balance sheet—resulting in a net zero on
the intercompany account.269
Bankruptcy Code section 363(c)(1) provides a debtor authorization “to enter into
transactions including the sale or lease of property of the estate, in the ordinary course of
business…,” and without notice or hearing, “[to] use property of the estate in the ordinary course
of business.”270 Insys asserted that the intercompany transactions were in the ordinary course of
business under 363(c)(1), and thus Insys should be able to continue without Court approval.271
264
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Thus, Insys claimed it was continuing intercompany transactions was necessary to maintain the
ordinary course of business.272
Additionally, Insys requested the Court grant administrative expense status to all postpetition intercompany claims, asserting that giving such status would ensure that each entity using
the cash management system continued to bear the responsibility for the transaction with affiliated
in the ordinary course of business.273 Bankruptcy Code section 503(b)(1)(A) states “after a notice
or a hearing there shall be allowed, administrative expenses, including the actual, necessary costs
and expenses of preserving the estate.”274
Again, on June 11, 2019, the Court granted Insys’s motion on an interim basis pursuant to
Bankruptcy Code 363(a) and 503(b)(1)(A), authorizing Insys to continue Intercompany
Transactions in the ordinary course of business and granting post-petition intercompany
administrative expense priority. 275 Finally, on July 7, 2019, the Court granted Insys’s motion on
a final basis.276
ii. Certain Prepetition Obligations Related to Cash Management System
Next, Insys requested the Court to authorize Insys to pay prepetition obligations related to
the cash management system.277 Further, Insys stated that payment would prevent unnecessary
disruptions to the cash management system and would ensure that Insys’s receipts of funds were
not delayed.278 Insys claimed that the payments would not prejudice any parties in interest,
because the banks likely had setoff rights, and payment of prepetition fees should not alter the
rights of unsecured creditors in these chapter 11 cases.279 A right to setoff is when a creditor holds
their claim against a debtor in the creditor’s “own property,” compared to a security interest where
the creditor holds their claim in the debtor’s property.280
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Pursuant to Bankruptcy Code sections 363(b) and 105(a), Insys sought authority to pay any
prepetition bank fees, as well as to continue making payments on account of such obligations postpetition in the ordinary course of business.281 On July 7, 2019, the Court authorized Insys to pay
any pre-existing bank fees, and stated that if there were any outstanding fees left, Insys was to pay
them as a ‘Bank Fee’ for the maintenance of the cash management system.282
iii. Waiver or Extension of time to Comply with Requirements of §345(b)
Next, Insys requested the Court to grant a waiver of the requirements of Bankruptcy Code
section 345(b).283 345(b) states “a debtors cash deposits and investments during a chapter 11 case
and authorizes such deposits or investments to yield the maximum reasonable net return on that
money.”284 For deposits not insured or guaranteed by the U.S., or by any instrumentality of the
U.S., or not backed up by the full faith and credit of the U.S., 345(b) requires the debtor to obtain
an adequate corporate surety from the entity that the money was deposited or invested in favor of
the U.S., unless the Court stated otherwise.285 Insys may require the entity may to deposit
government securities in accordance with 331 U.S.C. § 9303, which provided that when required
to give a surety bond, a person “may instead provide an eligible obligation designated by the
Secretary or the Treasury as an acceptable substitute for a surety bond.”286 Similarly, UST
Operating Guidelines provided that chapter 11 debtors are required to deposit all estate funds into
an account with an authorized depository that agrees to comply with the U.S. Trustee requirements,
among other things.287
Thus, Insys asserted that the cause requirement existed 345(b), to satisfy the waiver
requirements.288 In support, Insys asserted that all of the bank accounts were maintained by
authorized depositories, except for three investment accounts and employee stock option accounts.
which were maintained by highly rated, nationally charted banks, subject to supervision of national
banking regulators.289 Further, Insys claimed moving funds from the accounts would have
281
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disrupted the cash management system and inhibited their ability to operate “efficiently and
economically.”290 Similarly asserting that if forced to obtain a bond secured by receiving a
corporate surety, if could be obtained at all, it would have been prohibitively expensive.291
Thus, Insys declared that the Court should waive the requirements of 345(b) in these
chapter 11 cases.292 If such waiver was deemed inappropriate, Insys requested an extension to
engage in a discussion with the U.S. Trustee to make other acceptable arrangements.293 Insys
requested a 45 days extension to come into compliance with the Bankruptcy Code section 345(b)
requirements, or to make other acceptable arrangement with U.S. Trustee accepted.294 Insys
claimed that they had more than 200 creditors and thus, there was cause to grant their waiver
request pursuant to Local Rule 2015-2(b).295 If the Bankruptcy Code section 345(b) requirements
were not waived, Insys stated their requested extension to comply with 345(b) was warranted.296
On June 11, 2019, the Court entered an interim order granting Insys’s request for a 45
extension, without prejudice, that would have enabled them to come into compliance with
Bankruptcy Code section 345(b), or to make other arrangements the U.S. Trustee agreed to.297
Insys clarified that they reserved the right to further request an extension or waiver for the
requirements of 345(b).298 Finally, on July 7, 2019, the Court issued the final order granting
Insys’s request.299
iv. Maintenance of Insys’ Bank Accounts and Business Forms
Further, Insys requested the Court permit maintenance of their existing bank accounts,
claiming that if forced to comply with UST Operating Guidelines, their ordinary financial
operations would be severely disrupted, causing inefficiency, increased administrative burdens,
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and creating unnecessary expenses.300 The UST Operating Guidelines required chapter 11 debtors
to: (1) establish one account for all debtor-in-possession tax paying estate funds; (2) exchange
existing accounts with new debtor-in-possession accounts; (3) maintain a separate debtor-inpossession account for cash collateral; (4) bear “debtor in possession” on their business forms; and
(5) have Insys’s bankruptcy number and type on the business forms.301
Insys claimed that if forced to open new debtor-in-possession accounts, they would have
to modify their cash management system, forcing them to reconstruct it entirely.302 Insys asserted
that the accountants would have changed their focus to opening these accounts, diverting their
attention from daily responsibilities during the crucial the critical chapter 11 cases.303 Further,
Insys claimed that such requirements would have increased operating costs, and that delays caused
by the reconstruction would have negatively impacted their ability to operate their business while
they tried to make these arrangements.304
Similarly, Insys requested permission to maintain their existing business forms, which they
used in their ordinary course of business from time to time.305 Insys claimed that adhering to the
strict guidelines from the UST Operating Guidelines above, along with the Local Rule 2015-2(a)
would have unnecessarily increased their expenses and risk confused their customers, suppliers,
and employees.306 Local Rule 2015-2(a) provides that when debtors exhaust their existing
business forms, a chapter 11 debtor must order new ones that are labeled with “debtor-inpossession” and the bankruptcy numbers that correspond with it.307
They further stated that they believed, to reduce expense and delay, they should have been
authorized the use of their old forms, so long as when they were to order new forms, they would
comply with UST Operating Guidelines and Local Rule 2015-2(a) by adding debtor-in-possession
along with the lead bankruptcy number.308 Further, Insys would have added such information to
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their checks generated within 10 business days after the date of entry of the proposed interim
order.309
For the forgoing reasons, Insys claimed that all benefits sought by implementing UST
Operating Guidelines or the Local Rule 2015-2(a) would have been outweighed by the expenses
and inefficiencies they would have faced in the process.310 Therefore, Insys stated their request
for authority to maintain their bank accounts and business forms should have been granted for
these chapter 11 cases.
On June 11, 2019, the Court ordered Insys to contact all the banks where they maintained
accounts to a UDA with the U.S. Trustee within 15 days of the interim order, to provide the banks
with their identification number, and to identify the bank accounts that the banks held as being
accounts held by a debtor-in-possession.311 The Court further ordered Insys to contact all banks
that were not party to a UDA with the U.S. Trustee and use their “good faith efforts to cause such
banks to execute a UDA in a form prescribed,” by the U.S. Trustee within 45 days of the entry of
the interim order.312 On July 7, 2019, the Court issued its final order which finalized their decision
made in the Interim order.313
v. Bankruptcy Rule 6003(b)
Bankruptcy Rule 6003(b) provides that a court may issue an order granting, “a motion to
use, sell, lease, or otherwise incur an obligation regarding property of the estate including a motion
to pay all or part of the claim that arose before the filing of the petition,” within 21 days of filing
the petition, if necessary to avoid immediate and irreparable harm.314 Insys claimed that they
would suffer irreparable harm if the relief under Bankruptcy Rule 6003(b) was not promptly
granted.315 The Court granted this motion in its interim order on June 11, 2019, and finalized its
decision, after the final hearing, on July 7, 2019.316
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vi. Bankruptcy Rule 6004(a) and (h) Waivers
If the notice requirement applied, Insys claimed that the information in the motion
supported their need for a waiver of the notice requirements under Bankruptcy Rule 6004(a) and
a stay order providing the relief requested under Bankruptcy Rule 6004(h).317 On June 11, 2019,
the Court entered an interim order, granting the motion under Bankruptcy Rules 6004(a) and
6004(h), deeming the adequate circumstances to grant such motion.318 The Court deemed the order
under 6004(a) to be effective immediately.319 The Court issued a final order on July 7, 2019,
granting the motion on a final basis.362
b. Motion to Pay Utility Providers
Next, Insys filed a motion requesting the continuation of utility service and approval of
adequate assurance to pay the utility company.320 As of the Petition Date, Insys incurred expenses
for utilities, including electricity, gas, water, sewage, technology, and waste removal.321
Approximately thirteen utility providers provided service to Insys collectively amounting to about
$72,000 a month.322 Insys claimed to rely on the utility providers to service their various
businesses in Arizona and Texas, providing service to their employees, vendors, and customers.323
Bankruptcy Code section 366 allows Insys’s request for the “dual purpose of protecting [Insys]
from utility service cutoffs upon bankruptcy filing and providing utility companies adequate
assurance that [Insys] will be able to pay for post-petition services.” 324
Under Bankruptcy Code section 366, “during the first thirty days of a chapter 11 case, a
utility company may not alter, refuse, or discontinue services to a debtor solely because of any
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unpaid prepetition amounts.”325 However, 366 also provides that after the thirty days, utility
providers may alter, refuse, or discontinue service is the debtor fails to provide a satisfactory form
of ‘adequate assurance’ of payment of post-petition utility services.326
On June 11, 2019, after only two days, the Court granted Insys’ motion on an interim basis,
granting Insys the authority to deposit $36,000 of adequate assurance into a separate account,
which was payable to each provider in their given amounts.327 On July 3, 2019, after the final
hearing, the Court issued a final order granting Insys the authority on a final basis.328
c.

Insurance Policies, Surety Bonds, & Related Obligations

On June 10, 2019, Insys filed the motion requesting the authority to continue to maintain
their insurance policies and surety bonds, to honor all relating obligations, and to modify the
automatic stay relating to the workers’ compensation policies.329 The nature of Insys business
required them to maintain the General Liability and Property Policies, the Professional Liability
Policies, the Worker’s Compensation Policies (“WC Policies’) and the Global Clinical Trials
Policies (“Clinical Trial Policies”) (further discussed below and collectively, the “Insurance
Policies”) through several different insurance carriers (the “Insurers”).330 As of the Petition Date,
Insys believed they paid all fees related to the Insurance Policies, and were estimated to accrue
fees from other obligations, including broker or advisor fees, assessments, and taxes, amounting
to approximately $187,500.331
Insys obtained insurance, including general liability, products liability, property,
automobile, crime, equipment, marine cargo, umbrella, and excess liability policies (collectively,
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the “GLP Policies”).332 Similarly, Insys paid $2,817,000 for the GLP Policies.333 The GLP
policies covered directors’ and officers’ liability, fiduciary liability, employment practices
liability, and professional liability, Insys paid about $1,581,000 in the aggregate.334 For Insys’s
WC Policies, Insys paid $139,000 in premiums for the policy year, ending September 1, 2019.335
Insys believed they paid all prepetition amounts on their Insurance Policies but requested
relief to be cautious.336 In addition to the Insurance Policies were the clinical trial policies, which
shielded Insys from liability related to clinical trials conducted in foreign countries such as
Argentina, Canada, Italy, Mexico, and Poland.337 The clinical trial policies were approximately
$43,000 for 2019, expiring in December, six months after the Petition Date.338
Insys requested relief to satisfy their Insurance Policies and Surety Bonds, under
Bankruptcy Code section 503(b)(1), which provides that administrative expenses, including “the
actual, necessary costs and expenses of preserving the estate” were permitted after notice and
hearing.339 Similarly, pursuant to Bankruptcy Code section 362(a)(1), Insys requested
modification for WC Policy Claims, which would have allowed Insys employees to proceed with
such claims.340 Insys argued failing to modify the WC Policy would cause employees to leave or
harm employee morale, in turn “severely disrupt[ing] Insys’s business and prevent[ing] a
successful reorganization.”341 On July 3, 2019, the Court granted Insys requests Insys’s motion
regarding Insurance Policies and workers compensation.342
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3. Part Three of First Day Motions: Prepetition Obligations
Prepetition obligations were payments and services that Insys agreed to before filing for
chapter 11 proceedings, and these motions requested authority from the Court to pay and honor
such obligations.
a. Prepetition Claims for Critical Vendors
First, Insys filed a motion requesting the authority to pay certain prepetition claims for
certain critical vendors, and for the Court to confirm the administrative expense priority of
undisputed and outstanding prepetition claims.343 Pursuant to Bankruptcy Code sections 105(a),
363(b), and 503(b), Insys requested entry the authority to pay non-priority, prepetition claims to
vendors, whose goods and services were essential to Insys’s operations (“Critical Vendors
Claims”).344 These Critical Vendors (“Critical Vendors”) provided various outsourcing
operations, such as: storing, monitoring, packaging, and distributing services, also providing
equipment and equipment-related services for manufacturing Insys’s products, including Marketed
Products, Subsys and Syndros (the “Marketed Products”), and developing Pipeline Products that
were not ready for commercial use.345 Insys requested the authority to establish a trade agreement
to pay the Critical Vendor Claims through, consisting of terms that were just as favorable as ones
made in the contracts before the filing, or any other recent contracts.346
Further, Insys claimed that paying the Critical Vendors was important because Insys’s
operations were highly specialized and relied on the Critical Vendors’ key raw ingredients.347
Insys claimed that switching vendors on such short notice would have been impractical and the
business would be forced to jump a lot of hurdles to get new vendors approved, due to how heavily
regulated Insys’s business was.348 Changes made to a vendor’s product would have to be approved
and comply with regulations on a federal and/or state level, which would likely cause further
expense and delay in Insys’s operations, especially for Insys’s Pipeline Products, which had to be
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produced in approved facilities before they could be approved for marketing.349 Insys claimed that
even minor changes cost millions and “required months to a year of regulatory study.”350
In addition, Insys lacked many long-term agreements because it operated on a purchase
order basis.351 If Critical Vendors failed to supply Insys with necessary services or goods, it would
cause delays in producing the Marketed Product’s, which would have “adversely affect[ed] the
willingness of wholesale pharmaceutical distributors or special retail pharmacies (the
“Customers”) to do business with the [Insys] in the future.”352 Thus, Insys claimed that failing to
retain the Critical Vendors could have a “material adverse effect on [Insys’s] cash flow,” and could
have hindered Insys’s ability to maximize their estate value.353
Further, if the Court rejected Insys’s request to pay the nonpriority, prepetition Critical
Vendor Claims, Insys claimed they would be unable to adhere to FDA regulations and clinical
studies for the Marketed Products.354 Failing to perform the required clinical studies “could result
in a withdrawal of [Insys’s] marketing authorizations or approvals.”355 Further, Insys claimed that
to rely on “highly specialized contract research organizations,” (“CRO”s) to conduct their clinical
trials on both the Marketed and Pipeline Products.356 Similarly, Insys claimed to rely on “thirdparty medical institutions clinical investigators, and contract laboratories,”(together with CROs
(“Clinical Trial Vendors”).357 The Clinical Trial Vendors conducted clinical research, and failing
to pay their prepetition claims could have caused them to cease enrollment of new patients , which
was likely to delay or terminate ongoing trials, which would have negatively impacted Insys’s
business.358 Moreover, many of the Critical Trial Vendors performed services for which no
alternative vendors existed, and even where an alternative vendor existed, switching vendors
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during ongoing clinical trials would have “cause[d] severe disruption and impede[d] the results of
such studies.”359
Insys and their restructuring professionals worked to develop a process that identified the
Critical Vendors and quantified the relief necessary to avoid “immediate and irreparable” harm to
Insys.360 The process provided the following factors: type of good/service provided by
vendor/supplier; whether goods/services were essential; whether contract or a purchase order
basis; whether full or partial payment was necessary; alternative vendor options; whether failing
to pay the vendor jeopardized Insys’s valuable proprietary interest in their products.361
Insys requested to use appropriate efforts to require each Critical Vendor to “provide as
favorable trade terms, practices, and programs, including credit limits, pricing, cash discounts,
timing of payments, allowances, product mix, availability, and other programs, as those trade
terms, practices, and programs in place in the 120 days prior to the Petition Date.”362 Thus, Insys
requested the Court require each Critical Vendor to enter into a trade agreement, as a condition of
a Critical Vendor Claim.363 If Trade Agreements were not approved, Insys requested limited
authority to pay Critical Vendor Claims because Insys assumed that Critical Vendors were likely
to cease timely performance, or delivery, of goods or services that were critically important to
Insys’s business.364
Additionally, Insys addressed pre-petition outstanding orders with various manufacturers,
suppliers, and vendors for good or services (“Outstanding Orders”), stating these obligations were
to be treated as general unsecured claims in the chapter 11 cases.365 Therefore, under Bankruptcy
Code section 503(b), Insys requested the Court to grant administrative expense priority to satisfy
such obligations in the ordinary course of business.366
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On June 11, 2019, the Court entered an Interim Order, granting Insys’s requests as
explained above.367 Finally, on July 3, 2019, the Court issued a Final Order affirming the grants
under the Interim Order.368
b. Prepetition Claims for Taxes
Pursuant to Bankruptcy Code sections 105(a), 363(b), and 507(a), Insys requested
authority, without direction, taxes, fees, and other charges later established upon audit or
otherwise, that were owed for periods prior to the Petition Date (collectively, the “Taxes and
Fees”).369 Insys was required to pay certain Taxes and Fees, including: (a) Business and
Commercial Activity Taxes, (b) Franchise Taxes, (c) Personal Property Taxes, and (d) Regulatory
Miscellaneous Fees.370 These payments were usually for a large sum of money, for example, in
2018, Insys paid an aggregate amount of approximately $2,800,000 in Taxes and Fees. 371 In
September 2018, Insys paid $1,859,590 to cover following year.372 Moreover, as of the Petition
Date, Insys expected to incur fees related to five prescription strength doses of their Subsys
product, and one dose Syndros product.373 The FDA had not announced the applicable program
fee rates for 2019, so Insys claimed that they could not anticipate the August 2019 invoice
amount.374
Insys claimed to have paid on time, but still anticipated to incur approximately $371,900
in Taxes and Fees during the chapter 11 cases.375 Thus, Insys sought to enjoin Tax Authorities
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from taking actions that interfered with the chapter 11 cases, or with Insys’s ongoing business.376
As of the Petition Date, Insys believed to have paid all fees, but still requested the authority to pay
any prepetition taxes owed, including any amount later determined by Insys.377
Insys argued that failing to pay these Taxes and Fees risked causing an increase of secured
claims held by Taxing Authorities against their estates.378 Moreover, Insys argued that without
the grant of relief requested, many Taxing Authorities could have over secured claims against
Insys’s estates related to the Taxes and Fees.379 Under Bankruptcy Code section 506(b), over
secured Claims may accrue interest during a chapter 11 case.380 Insys argued that certain Taxing
Authorities may have had the ability to hold Insys’s directors and officer’s personably liable if
they failed to pay these taxes.381 Further, Insys asserted that it would harm their reputation and
potential ability to sell their two most revenue generating products, by failing to pay these Taxes
and Fees.382 On July 3, 2019, the Court granted Insys’s motion for Taxes and Fees.383
c. Motion to Approve Established Procedures & Schedules for Estimation Proceedings
Under Bankruptcy Code sections 105(a) and 502(c), Insys requested the Court enter an
order establishing procedures to estimate certain categories of claims.384 Specifically, Insys
requested the Court approve: (1) a proposed discovery timeline and an estimation proceeding
before confirming the plan, (2) the proposed order protecting confidential information produced
by the estimation process, (3) estimated actual and compensatory damages subsumed in each
Claim Category for purposes of plan allocation and settling claim distribution reserves, and (4)
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subordination of penalty and punitive damage claims.385 Bankruptcy Code section 502(c) requires
the Court to estimate “any contingent or unliquidated claim.”386 Insys clarified that they sought
the Court to find the claims in category 4 to be subordinate to all general unsecure claims, including
actual and compensatory claims, not to estimate liability with respect to the individual Claims.387
Insys believed that established estimation proceedings were appropriate to avoid delay and ensure
transparency for all parties participating in the process in cases like theirs with such uncertain
litigation costs.388 Insys hoped that the chapter 11 process would serve as a catalyst for settlement,
expecting that setting a definitive schedule would prove to be a constructive framework for
potential negotiations.389
Insys’s proposed the following procedures and schedule for Claims Categories estimation
proceeding, by first serving their report, including expert analysis and good faith estimates of their
general unsecured liability in the Claims Categories, within five days after entry of the proposed
scheduling order.390 Next, within 10 days entering the proposed scheduling order, any interested
party, that sought to submit evidence in connection with the estimation hearing, was to file a notice
of participation, and was to file a notice served on Insys and other participants, providing their
decision to use and expert or not, and the identity of the within 21 days after the entry of the
proposed scheduling order.391
When Insys received a party-in-interest’s participation notice, they gave that party access
to Insys’s documents.392 Any interested party had 24 days after entry of the proposed scheduling
order to make additional fact discovery requests that were not already made accessible by Insys.393
Responses and objections were to be served on Insys and the party who made the initial request
within 21 days of such request.394 Parties had up to 14 days after service of the responses and
385

Docket 29 at 5.

386

Id. at 12; 11 U.S.C § 502(c).

387

Id. at 5.

388

Id. at 14.

389

Id. at 11.

390

Id. at 15.; See also pages 15-17 for estimation procedures and Exhibit A for proposed scheduling order.

391

Id. at 15-16.

Id. at 16; Insys’s documents included those produced in connection with various investigations and actions, and
pleadings and settlements also related to those actions.
392

393

Id.

394

Id.

50

production to make fact depositions.395 Within 15 days of the General Bar Date or the completion
of fact depositions, whichever came later, parties were to provide notice of their intent to use expert
testimony regarding Insys’s liability for one or more of the Claims Categories.396 Then, if Insys
sought to present expert rebuttal reports, they were to serve them within 14 days of service of the
expert reports, and all parties’ expert were to be available for a deposition within 14 days of service
of such rebuttal reports.397
An emergency hearing could be requested by any party at interest, but absent such request,
a hearing to estimate liability for Subsys Claims in each Claim Category would be held, if the
Court was available, within 15 days of the completion date for expert depositions.398 The parties
were to receive copies of exhibits relating to the estimation proceedings seven days prior to the
estimation hearing, and pre-trial briefs were to be filed with the Court four business days prior to
the estimation hearing.399 Additionally, Insys requested that the Court approve their proposed
order to protect disclosure of individuals medial information, that was classified as confidential by
HIPPA.400
Finally, Insys requested the Court to maximize all claims for actual and compensatory
damages by subordinating all claims that sought.401 Bankruptcy Code section 726(a)(4) states
“any fine, penalty, or forfeiture, or for multiple or exemplary, or punitive damages,” are
subordinated to general unsecured creditors in chapter 7.402 However, according to case law,
section 723(a)(4) is also applicable to chapter 11 cases through § 1129(a)(7).403 Therefore, Insys
requested the Court to prioritize actual and compensatory damages making all claims that sought
penalties subordinate to all general unsecured claims.404 Similarly, many objections argued that
the proposed estimations failed to provide adequate justice for their action and were fundamentally
395
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one-sided.405 On July 2, 2019, Insys entered an agreement with the Creditors’ Committee and
certain State Attorneys General regarding estimation procedures.406
Insys began negotiating with the Creditors’ Committee, and certain state AGs to come to
an agreement on the procedures as it pertains to this motion.407 During the adversary proceedings,
the Court entered the Agreed Order Regarding Estimation Motions, PI Motion, and Approving
Case Procedure, which exemplified all the negotiations the aforementioned parties worked
toward.408 The agreed order provided the Case Protocol, which was also described in the
disclosure statement to the second amended plan.409 When the Court approved the disclosure
statement, therefore approving the Case Protocol, Insys withdrew this motion.410
VI.

The 363 Sale

a. Motion for Sale of Property Under 363(f)
After facing extensive litigation and related expenses, and as Subsys revenues substantially
declined, Insys developed a “multi-faceted” chapter 11 plan to resolve their liabilities, to maximize
the value for their stakeholders.411 The plan included increasing cash value of their estates and
Objection of Class Creditors to Debtors’ Motion for (I) Entry of Orders Pursuant to 105(a) and 502(c) (A)
Establishing Procedures and Schedule for Estimation Proceedings and (B) Estimating Debtors Aggregate Liability
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Orders Pursuant to 11 U.S.C. Sections 105(a) and 502(c) (A) Establishing Procedures and Schedule for Estimation
Proceedings and (B) Estimating Debtors Aggregate Liability for Certain Categories of Claims, (II) Entry of
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using that value to pay claimants instead of using it to fund unnecessary chapter 11 and other legal
costs.412 A part of the plan was to solicit bids for an auction for the sale of Insys’s assets related
to Subsys, Syndros, their Pipeline Products, and other CBD products.413 Insys requested the
approval of the bidding and auction procedures (the “Bidding Procedure”).414
Pursuant to all applicable law, Insys requested the following: (1) authorization the Bidding
Procedures, (2) asset auctions to be held on August 2, 2019, (3) the Court to schedule a hearing to
consider the proposed sale transactions, (4) authorization of notice procedures for all bidding
procedures, and (5) authorization and approving procedures for the assumption and assignment of
contracts and leases, and (6) any other related relief.415 Further, under Bankruptcy Code section
363(f ), Insys requested that, the assets be sold “free and clear of any lien, claim, interest and other
encumbrance.”416 Moreover, Insys asked the Court to apply Bankruptcy Code section 365(a),
approving Insys, as debtor in possession, to assume or reject any executory contract or unexpired
lease.417 Insys argued that their assumption of contracts and leases satisfied Bankruptcy Code
section 365 and would be a sound exercise of their business judgment.418
Following an entry of the Bidding Procedures Order, Insys requested the Court’s approval
of one or more orders that authorized the sale of the assets, except those permitted by Insys, and
the assumption and assignment of proposed assumed contracts and leases in connection with the
Sale Transactions.419
As mentioned, Insys employed JMP to serve as their investment banker and to solicit sales
before these chapter 11 cases.420 JMP contacted 83 parties, providing them with a memorandum
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containing confidential information regarding Insys’s business.421 Four of the 83 parties
expressed interest in a potential sale or license of rights relating to Subsys.422 By the end of January
2019, only three of the interested entities had submitted written proposals while the fourth
indicated that it intended to submit a written proposal in late April 2019.423
As stated above, in April 2019, Insys employed Lazard to “explore opportunities to engage
in a strategic partnership or financing transaction” with respect to Insys’s products.424 Lazard was
therefore transferred all of JMP’s work on the Subsys related transaction, and continued marketing
Insys’s other products.425 Lazard contacted 51 entities and 28 were granted access to a virtual data
room that contained confidential information regarding the assets they expressed interest in.426
Four of the 28 who received access expressed interest in the transaction process and were granted
access to another virtual room which had additional confidential information regarding the
Pipeline Products.427 By March 2019, Insys had four non-binding indications of interest for some
of their Pipeline Products and three of those four were selected to continue the next round of
submissions.428 Presentations were held to management and the one interested party conducted an
on-site visit at Insys’s corporate office in April that same year.429 Unfortunately, as of the Petition
Date, all interested parties withdrew their offers.430
In support of this motion, Andrew Yearly’s declaration was filed.431 Yearly was managing
director for Lazard’s Restructuring Group, and worked for Lazard since 1998, claiming he could
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testify to its credibility and success in complex financial restructurings. 432 Yearly attested that
Insys’s Bidding Procedures were designed to facilitate the most “robust and competitive” bidding
process possible under the circumstances.433 Furthermore, Yearly stated that the Bidding
Procedures provided an adequate framework, allowing Insys the flexibility to consider each bid
carefully to make a strong evaluation of which bid to select.434 For example, the option to purchase
a part of the assets without having to bid for all relating assets.435 Finally, Yearly supported
Insys’s decision to reserve their rights to forego the sale of assets if the bids were not sufficient.436
Further, Yearly believed that the Insys’s proposed post-petition sale process was reasonable and
appropriate given the prepetition marketing efforts and prior due diligence conducts.437
The Post-Petition sales consisted of marketing Insys’s assets related to: (1) Subsys; (2)
Syndros, and CBD related products; (3) epinephrine; (4) Naloxone; (5) Buprenorphine. 438 Insys
consulted their advisors and the Creditors’ Committee and developed Bidding Procedures that
governed some aspects of the Post-Petition sales.439 On July 2, 2019, the Court rendered an order
that approved the Bidding procedures.440 The Bidding Procedures allowed for parties to submit
bids on individual or combinations of the assets of Insys, and afforded Insys the ability to reject
offers that did not prove sufficient for the assets.441
b. Hikma Transaction
On August 5, 2019, Insys and Hikma Pharmaceuticals USA, Inc. (“Hikma”), entered into
an asset purchase agreement for Insys’s epinephrine 7mg and 8.5mg unit-dose nasal spray
products, as well as the naloxone 8mg unit-dose nasal spray products (collectively “Hikma
Products”).442 The purchase agreement agreed to sell to Hikma the Hikma Products pursuant to
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Bankruptcy Code section 363(b).443 Along with the Hikma Products, Insys agreed to sell certain
equipment and liabilities related to the products (collectively “Hikma Purchased Assets”).444
Hikma agreed to pay Insys $17,000,000 at the closing of the transaction, as well as the cure costs
for the purchased contracts that were assumed and assigned to Hikma under the asset purchase
agreement.445 On August 22, 2019, the Court entered an order approving of the Hikma Asset
Purchase Agreement, as well as the sale to Hikma.446 The transaction closed on August 29,
2019.447
c. Chilion Transaction
On August 6, 2019, Insys agreed to sell to Chilion Group Holdings US, Inc. (“Chilion”),
Insys’s: (1) CBD formulations; (2) THC programs of Syndros Oral Dronabinol Solution; and (3)
Buprenorphine products, (collectively “Chilion Products”).448 Insys also agreed to sell Chilion
certain related equipment and other assets (collectively “Chilion Purchased Assets”).449 In return,
Chilion agreed to pay Insys $12,200,000 in cash at the close of the transaction.450 In addition,
Chilion agreed to pay cure costs for the purchased contracts, and the lease for Insys’s Round Rock
Facility, as well as to assume certain liabilities.451 Chilion also agreed to offer employment to
certain employees who worked for Insys.452 On August 23, 2019, the Court rendered an order
approving the Chilion asset purchase agreement and the sale of those assets.453
However, on October 23, 2019, Insys and Chilion amended the asset purchase agreement,
and filed a copy with the court, dated October 25, 2019.454 The amendment included Insys’s
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agreement to sell Chilion additional equipment, as well as intellectual property, and a lease
agreement for Insys’s Ellis Facility.455 In exchange, Chilion agreed to pay an additional $105,000
in cash at the closing of the transaction.456 Chilion agreed to pay Insys for the funds lost due to
the delay, which included; (1) $856,797.26 in cash at the execution of the amendment; (2) payment
to the FDA or to Insys as reimbursement of an amount equal to the aggregate fee amount which
was payable pursuant to the Prescription Drug User Fee Act with respect to Syndros; (3)
reimbursement in cash to Insys for any third party costs and expenses up to $100,000 dollars, to
be paid at the closing of the transaction; and (4) all reasonable costs and expenses up to $200,000
in the aggregate to Insys for certain professional services performed by Insys’s Advisors, which
we to be paid at closing.457 The Amendment provided certain other negotiations to the purchase
agreement, and stated that the transaction would close by October 31, 2019, which it did.458 The
parties agreed that the employees would be paid 107.5% of what Insys had originally paid them
for the services.459
d. BTcP Subsys Transaction
On September 1, 2019, Insys and BTcP Pharma, LLC (“BTcP”) entered into an asset
purchase agreement for strengths, doses, and formulas in the world of Insys’s Subsys Product.460
BTcP agreed to assume certain specified liabilities, including the cure costs, as well as post-closing
royalty payments based on the sale of Subsys.461 This royalty was in connection with some of
BTcP’s products, and was only until the expiration of the last to expire orange book listed patent
in respect to the products.462 The estimated number of royalties Insys was to receive was
approximately $52 million over a 15 year period.463 Further, prior to the second anniversary of
the closing date, BTcP agreed to pay Insys the sum of the total closing date accounts annually
collected by BTcP and the value of Subsys product transferred to BTcP at the closing, even if it is
454
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sold by BTcP at Insys’s cost of acquisition of the inventory.464 This later group of payments were
estimated to be $8.2 million dollars.465 Insys also agreed to pay all costs incurred from thirdparties due to the observation of the FDA form 483 letter related to Subsys products, until
September 30, 2019, and after that BTcP agreed to pay those costs.466 On September 19, 2019,
the Court approved the transaction, which closed on September 26, 2019.467
e. Pharmbio Subsys Transaction
On September 25, 2019, Insys and Pharmbio Korea, Inc. (“Pharmbio”) entered into an asset
purchase agreement for specific intellectual property, records and other assets related to the
strength, doses, and formulations of Subsys, which covered the territories excluded in the BTcP
sale.468 Insys agreed to sell, transfer, and assign these products to Pharmbio.469 In exchange,
Pharmbio agreed to pay $1,200,000 to Insys at the closing of the transaction.470 The Court
approved the Pharmbio asset purchase agreement on October 16, 2019, and when the second
amended plan was filed, this transaction had not been closed.471 Finally, the sale went through in
December, and Insys started to make transfers to Pharmbio.472
f. De Minimis Sale to Renaissance Lakewood, LLC.
On December 13, 2019, Insys filed a motion requesting the Court approve their procedures
for the expedited sale, transfer or abandonment of De Minimis Assets, and entry into exclusive
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Encumbrances, and Other Interests Pursuant to Bankruptcy Code section 105 and 363(b), (f) and (m) and (3) Granting
related Relief. Docket 767.
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Debtor-In-Possession Monthly Operating Report for Filing Period December 1 through 31, 2019 Filed by Insys
Liquidating Trustee. Docket 1241 at 7.
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auction and Sales Agreement.473 The de minimis assets were those that Insys used to operate their
pharmaceutical business, including “lab equipment and related materials, general office
equipment, including printers, copiers, and intellectual property that Insys determined to be too
costly to pay fees on.474 Pursuant to Bankruptcy Code section 363, Renaissance Lakewood, LLC
purchased these de minimis assets for $275,000.475 On December 16, 2019, the Court approved
the sale over the de minimis assets. 476
VII.

The Liquidating Plan Development & Filing

On September 17, 2019, Insys Filed their Joint Chapter 11 Plan of Liquidation (“Original
Plan”), the disclosure statement and other applicable documents.477 A disclosure statement is a
“document that must contain information concerning the assets, liabilities, and business affairs of
the debtor sufficient to enable a creditor to make an informed judgment about the debtor’s plan of
reorganization.”478 A new disclosure statement was to be filed with every amended plan.
a. Administrative Expense Claims, Professional Fee Claims, and Priority Tax Claims
Under Bankruptcy Code section 507(a)(2) and 507(b), Administrative Expense Claims
were claims were: (i) costs during the chapter 11 cases, that Insys needed to operate and preserve
their estate,; (2) professional fees; (3) all fees and charges assessed against the Estate under
Bankruptcy Rule 1911 through 1930 and the Tax Code; (4) “Allowed” claims that were deems
“allowed” in the Final order pursuant to Bankruptcy Code section 546(c)(2); and (5) cure claims,
which were cured by assignment of contracts of unexpired leases under Bankruptcy Code section
365(a).479 All Administrative Expense Claims were to be filed by September 9, 2019
(“Administrative Expense Claims Bar Date”), not including Professional Claims Fees (defined
below) and Administrative Expense Claims arising out of the ordinary course of business after the
473

Motion For Sale of Property Free and Clear of Liens under Section 363(f)(FEE) // Motion of Debtors Pursuant to
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Petition Date, which were to be filed by October 24, 2019.480 Similarly, so long as they were
properly and timely filed, and the Liquidating Trustee of the Court did not properly object (within
120 days after the Effective Date, or otherwise specified by the Court), the claim would become
an “Allowed Administrative Expense Claim.”481 If an objection was filed, the claim would only
be “Allowed” if deemed so by the Final Order, or if the Claim was settled or otherwise resolved
by the Liquidating Trustee.482
b. Professional Fee Claims
Professional Fee Claims (“Professional Fee Claims”) were claims made by professionals
for providing services, or incurring costs, during the chapter 11 cases, that were unpaid as of the
Effective date.483 These Claims were to be filed within 45 days after the Effective Date.484
Similarly, the Original Plan established the Professional Fee Escrow Account, which was an
interest-bearing account, funded on the Effective Date, by Insys with an estimated amount of all
of the Professional Fee Claims.485 On the Effective Date, or as soon as possible after, Insys was
required to transfer the Professional Fee Escrow Account to the ILT.486 If all professionals were
paid in full and no additional claims were pending, any remaining amount in the Professional Fee
Escrow Account was to transfer to the ILT Recovery Fund (“ILT Recovery Fund”), which was
established distribute all Allowed Non-PI General Unsecured Claims, and fund, with cash
available, all Non-PI General Unsecured Claims (cash available defined as, “Estate Distributable
Value”).487 If there were insufficient funds in the Professional Fee Escrow Account, the unpaid
Professional Fee Claims were to be reclassified as an Allowed Administrative Expense Claim.488
c. Summary of Classification of Claims and Interests
Classes
Class 1
Class 2

Claims and Interests
Secured Claims
Other Priority Claims

Status
Unimpaired
Unimpaired
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Id. at 30; See appendix for Allowed Administrative Expense Claim
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Id; See also section 7.5 of Docket 612.
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Id. at 22.
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Voting Rights
No (Presumed to Accept)
No (Presumed to Accept)

Class 3
Class 4
Class 5
Class 6
Class 7
Class 8
Class 9
Class 10
Class 11
Class 12

Trade and Other Claims
Insurance Related Claims
Hospital & NAS Monitoring Claims
DOJ Claims
SMT Group Claims
Personal Injury Claims
510(a)/(b) Subordinate Claims
510(c) Subordinate Claims
Intercompany Claims
Equity Interests

i.

Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired

Yes
Yes
Yes
Yes
Yes
Yes
No (Presume to Reject)
No (Presumed to Reject)
No (Presumed to Reject)
No (Presumed to Reject)

Original Plan’s Voting Procedures

The Original Plan provided that only holders of Classes 3-8 Claims were entitled to vote
to accept or reject the plan (the “Voting Classes”).489 A class accepted the Original Plan if: (1)
more than 2/3 the amount (dollar amount) of the holders of the claims in the Voting Class voted
to accept the plan, and (2) if more th½1/2 the number (number of claims) the holders of the Claims
in the Voting Class voted to accept the plan.490 Bankruptcy Code section 1126(f) made Classes 1
and 2 unimpaired, and deemed to have accepted the plan.491 Bankruptcy Code 1126(g) made
Classes 9 through 12 impaired, but were to receive nothing under the Original Plan, and therefore,
were deemed to reject the Original Plan.492
Bankruptcy Code section 1129(b) provides that if a class rejected the plan, or was entitled
to vote but failed to, Insys could cramdown those rejections or failures to vote by (1) seeking
confirmation anyway or (2) amending or modifying the Original Plan; if controversy arose out of
impaired, or unimpaired, claims or interests, the Court was to resolve that controversy before, or
on the Confirmation Date.493
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Id. at 33; citing 11 U.S.C. § 1126(f).
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Id.; citing 11 U.S.C. § 1126(g).
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ii.

Treatment of Claims
1. Unimpaired Claims

Class 1, Allowed Secured Claims, were to receive: (1) payment in full under Bankruptcy
Code section 506(a); (2) reinstatement under Bankruptcy Code section 1124; or (3) any treatment
making the claim unimpaired.494 Under Bankruptcy Code section 1126(f), Secured Claims were
unimpaired and deemed to accept the Original Plan.495 Class 2, Other Priority Claims were treated
in the same manner as class 1 as they were unimpaired and deemed to accept the plan.496
2. Impaired Claims
Under the Original Plan, Classes 3-8 were impaired and were entitled to vote.497 Class 3,
Trade and Other Unsecured Claims, were to be paid their Pro Rata share of: (1) 100% of all
Category 1 Distributions, (2) .5% of all Category 2 Distributions, or (3) 7% of Indemnity or
Preference Proceeds, which in the aggregate was not to exceed the cap on recovery.498 Class 4,
Insurance Related Claims, were to be paid their Pro Rata share, based upon the determination by
the ILT Claims Arbiter, of 68.5% of all Category 2 Distributions from the Insys Liquidation
Trust.499 Class 5, Hospital and NAS Monitoring Claims, was to receive its pro rata share from the
ILT, based upon the ILT Claims Arbiter’s determination, of 31% of all Category 2 Distributions.500
Class 6, DOJ claims, as restitution with respect to the Allowed DOJ Civil Claim and any additional
restitution claims, was to receive from the ILT, 31.4% of all Category 3 Distributions.501 However,
the DOJ Settlement Order prohibited the DOJ from receiving distributions for the Allowed DOJ
Civil Claim until the “GUC Recovery Reallocation Threshold,” was met, which was no greater
than $40.9 million.502 Class 7, SMT Group Claims, were to receive as restitution, from the ILT,
its Pro Rata share, determined by SMT Group Claims holders or by the Liquidating Trustee, and
if left undecided, 68.6% of Category 3 Distributions, 5% of any Products Liability Insurance
494

Docket 612 at 32.
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Id.
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Proceeds, and 100% interest in any Excess Products Liability Insurance Proceeds.503 However, no
Class 7 Claimant was permitted more than the amount of their claim.504 Class 8, Personal Injury
Claims, was to receive its Pro Rata share of 95% of any Products Liability Insurance Proceeds
from the VRT.505
Under Bankruptcy Code section 1126(g), Classes 9-12 were impaired and deemed to reject
the Original Plan.506 Under the Original Plan and Bankruptcy Code sections 510(a) and 510(b
Class 9, 510(a) and 510(b) Subordinated Claims, were subordinated.507 No further action was
required on these claims, as they were deemed, “expunged, discharged, released, and extinguished
without further action by or order of the Court.”508 Under the Original Plan and Bankruptcy Code
section 510(c), Class 10, 510(c) Subordinated claims, were treated in the same manner as Class 9,
but were subordinated.509 Class 11, Intercompany Claims, and Class 12, Equity Interest Claims,
were also deemed “expunged, discharged, released, and extinguished without further action by or
order of the Court,” and were not to receive any property under the Original Plan.510
d. Means for Implementation
Insys asserted that confirmation by the Court would have been proper, under Bankruptcy
Code section 1123 and 9019, as this structure, along with their trust formation transactions and
consolidation of estate value constituted a good faith compromise and settlement pursuant to
Bankruptcy Rule 9019.511 Insys Therapeutics, Inc. and all of its subsidiaries were substantively
consolidated into one chapter 11 case, meaning all property of the estate for each subsidiary was
deemed the property of the “consolidated estates.”512 Next, under Bankruptcy Code sections
1141(b) and (c), the Original Plan provided that all Assets were to vest in the ‘Liquidating
Debtors’, then were to be assigned to the appropriate trust, either the Insys Liquidation Trust or
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the Victims Restitution Trust, were free and clear of all “encumbrances, and liabilities of any
kind.”513 Similarly, Class 12 suggested that all equity interests, including all notes, instruments,
certificates, and other documents, that showed claims or interests in Insys, or their obligations were
to be deemed as discharged, and did not require further action or approval by the Court.514
e. The Trusts
i.
The Insys Liquidating Trust
After the Insys Liquidating Trust (“ILT”) was established, the Creditors Committee and
the SMT Group Representatives appointed a trustee (the “Liquidating Trustee”) to administer the
trust.515 The Liquidating Trustee had exclusive authority to perform “Authorized Acts.”516
Additionally, the Liquidating Trustee was responsible for paying taxes and filing tax returns and
retaining professionals without Court approval.517
The ILT was established within 5 business days of the Effective Date, and handled all nonpersonal injury unsecured claims (“Non-PI Unsecured Claims”).518 All Products Liability
Insurance Policies actions were reserved for the Victims Restitution Trust (the “VRT”) (discussed
below).519 The “ILT Operating Reserve,” held the ILT’s resources to pay claimants, and was
funded by $1 million of Insys’s available cash to pay the trust’s operating expenses.520 The
Liquidating Trustee replenished the ILT Operating Reserve as necessary to satisfy future estimated
operating expenses.521
The ILT’s obligations were a fundamental part of the Original Plan, which included: (1)
the responsibility and liability for Non-PI Unsecured Claims; (2) all operating expenses of the ILT,
(3) Administrative Expense Claims, Secured Claims, and Priority Claims; and (4) paying the ILT
Recovery Fund, the ILT Operating Reserve, and the Priority Reserve, in that order.522 The
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Creditors’ Committee appointed the ILT Claims Arbiter, who was paid $175,000.523 The ILT
Claims Arbiter determined the aggregate allocation of Estate Distributable Value for: (1) Class 4’s
Third Party Payor Claims (“TPPs”), and Insurance Ratepayer Claims (“Ratepayer”); and (2) Class
5’s Hospital Claims and NAS Monitoring Claims; However, the ILT Claims Arbiter was not
responsible for determining the individual amounts allocated within those Classes.524
Additionally, the ILT established a board (the “ILT Board”), that had general oversight of
the ILT, comprised of three members, two selected by the SMT Group Representatives and the
one selected by the Creditors’ Committee.525 When necessary, the ILT Board used the VRT
Insurance Negotiator, here ILT Insurance Negotiator, to assist in liquidating insurance claims.526
The ILT dissolved, and the Liquidating Trustee, ILT Claims Arbiter and ILT Board were
discharged, when: (1) all disputed Non-PI Unsecured Claims were resolved, (2) all ILT Assets
were liquidated, and (3) ILT made all required Distributions.527
ii.

The Victims Restitution Trust

The VRT was to be established within 5 business days of the Effective Date, but no earlier
than January 1, 2020.528 The VRT benefited Class 9 Allowed Personal Injury Claimants, and
handle and pay all Class 9 Claims.529 The VRT received all Products Liability Insurance Rights
and was the VRT Operating Reserve was funded by $1 million of Insys’s available cash.530 Before
the Confirmation Hearing, the Creditors Committee and the SMT Group Representatives, or from
a list of potential candidates provided by the Liquidating Trustee, appointed the VRT Claims
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Id.; see also at 46: The ILT was a “liquidating trust,” under Treasury Regulation § 301.7701-4(d), complied with
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Administrator, who was identified in the plan supplement.531 Periodic Distribution Dates, as
determined by the Liquidating Trustee, Distributions were to be made from the both trusts’
operating.532 If a Claim was disputed when the trust was established, but later resolved, the Claim
was to be treated as if it was resolved at the trust’s establishment, and was to receive distributions
in accordance with the applicable trust.533
iii.

The Parent Holding Trust

The Original Plan established the Parent Holding Trust (the “PHT”), which represented
100% Insys’s capital stock before the Original Plan cancelled their employees’ interest in the stock,
but the PHT was terminated after the interest in the stock was cancelled.534
f. Procedures for Unresolved Disputed Claims
The Original Plan stated a claim objections were to be served on the respective claim
holder, and filed with the Court no longer than 120 days after either the Effective Date, or the date
that a proof of claim is filed or amended, whichever came later, unless the Court specified
otherwise.535 Payments and distributions were made only when disputed claims were resolved,
becoming ‘Allowed Claims.’536 Disputed claims requiring Court involvement were to be
submitted to the Court for resolution.537 Holders of disputed claims that later became Allowed
Claims were only to be paid from undistributed available cash, having no cause of action against
any assets previously distributed.538
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g. Conditions Precedent to Confirmation of the Plan & the Effective Date
i.

Conditions Precedent to the Confirmation

The following conditions had to be met before the Original Plan was to be confirmed: (a)
the Original Plan was reasonable and accepted by Insys and the Creditors’ Committee; (b) the
Court found that all trust assets were free and clear of encumbrances and liabilities; and (c) Insys
and the Creditors’ Committee accepted the plan and plan supplement, including schedules, exhibits
and other applicable documents, and consistent with the other plan provisions.539
ii.

Conditions Precedent to the Effective Date

Until the following conditions were satisfied, the Effective Date was not to occur: (a) the
Confirmation Order was entered by the Court, and it was not stayed, modified, or vacated on
appeal; (b) all condition precedents, except the effectiveness of the plan, were satisfied or waived
by the authorized parties of the Trust Agreements, to create the Trust Formation Transactions; (c)
the Trust Agreements were effective according to the Original Plan; (d) the Priority Reserve, the
Professional Fee Escrow Account, and the Trust Operating Reserves were fully funded; (e) Insys
received all necessary documents for effectuating the plan; (f) all proceedings necessary to
implement the Original Plan were executed; and (g) all professional fees were approved by the
Court and fully paid, or were sufficiently paid in amounts for such fees, and after the Effective
Date, were placed in the Professional Fee Escrow Account, or contained in a professional fee
retainer,” pending Court approval.540
h. Effect of Confirmation
The Confirmation of the Original Plan was to be binding on every claim holder or any
impaired, or unimpaired, interest under the Original Plan.541 On the Effective Date, whether
Bankruptcy Code sections 105 or 362 applied or not, any injunctions or stays were to be
ineffective, unless they expired before then.542
Under Bankruptcy Code section 1125, Insys filed the disclosure statement to the Original
Plan, and a notice of hearing, enabling the Voting Classes to make an informed decision when
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voting on the disclosure statement.543 Before filing the Original Plan, Insys, the Creditors’
Committee, certain Personal Injury Claimants, Hospitals and NAS Children, Insurance
Ratepayers, certain non-MDL Municipalities, and the TPPs, conducted mediation between August
6 and August 31, 2019 (“August Mediation").544 Although the SMT Group Representatives were
not involved, after the August Mediation, Insys, the Creditors’ Committee, and the SMT Group
discussed the Claims Analysis Protocol (“Claims Analysis Protocol”) and the VRT Claims
Administrator (“VRT Claims Administrator”).545 The Claims Analysis Protocol established
general guidelines for the VRT Claims Administrator when determining whether a Class 9 was
allowed, and in what amount.546 The Original Plan and the VRT Agreement (“VRT Agreement”)
appointed the VRT Claims Administrator to administer, and otherwise resolve, the Class 9 Claims
under the Original Plan.547 The negotiations between Insys, the Creditors’ Committee, and the
SMT Group Representatives were incomplete at the time the Original Plan was filed.548
i. Objections
i.

Williamson Objection

On September 27, 2019, the County of Williamson, Texas (“Williamson”) objected to the
Original Plan.549 Under Bankruptcy Code section 1129(b)(1) and (2)(A), Williamson alleged that
the Original Plan’s provisions failed to provide fair and equitable treatment when dealing with
their secured claims, arguing that Insys failed to: (1) express when Williamson would be paid for
their Claims; (2) provide a clearly detailed proposed payment plan by stating that they intended to
pay Tax Authorities in installments or one lump sum,; and (3) provide interest for the taxes they
failed to pay in 2019, 12% per annum under Bankruptcy Code sections 511 and 1129.550
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ii.

S. Yu Objection

On October 8, 2019, an individual Shareholder of Insys Therapeutics common stock, S.
Yu (“Yu”), filed an objection to the Original Plan and the disclosure statement.551 Yu had 9 main
objections, including that: (1) instead donating the leftover funds from trusts to charity after
creditors were paid, the leftover funds should be placed in the PHT, belonging to 100% of
Shareholders; 552 (2) derivative lawsuit recoveries should not be transferred to Insys, when it was
the Shareholders who earned those profits and they should receive the benefit;553 (3) illegitimate
Creditors would receive undeserving distributions under this scheme, and suggested that they
establish a fair industry and legal guideline for elimination of illegitimate creditor claims,
including guidelines for arbitrations that set settlement costs and determined legitimate claims, and
also suggested implementing of a Shareholder’s Committee to help establish legitimacy of claims
and assure fairness;554 (4) liability was being directed at the Shareholders, arguing that the
Bankruptcy Court should direct those liabilities to the past Insys management who committed the
fraud; 555 (5) the Original Plan was “flawed and unreasonable,” based on assumptions, involved a
large number of ‘unvetted’ creditors, stating that: (a) the Original Plan’s settlements were
illegitimate, and (b) the sales were disappointing, with the exception of the Subsys sales to BTcP
and Pharmbio, and suggested that those assets be held in the PHT, giving Shareholders control
over such funds;556 (6) the illegitimate and Non-vetted claimants should not be entitled to vote,
and by doing so would have given them power over the Shareholders who already faced losses,
and suggested the Court eliminate voting rights all together, requesting this exception due to the
circumstances of the case, which could lead to illegitimate creditors voting on the Shareholders’
outcome;557 (7) distribution percentages for Claimants were not proper, stating that class 5 had a
particularly high impaired distribution percent which played a part in the distribution devaluation.
Yu claimed Insys would have been profiting and would have had sufficient funds to carry them
through if the fraud around the opioid crisis never occurred.558 Yu believed that the wrongs would
be better resolved by being brought against the wrongdoers, rather than liquidating the company,
gave away the illegally earned money, and the victims of such fraud would have been covered by
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insurance;559 (8) only legitimate creditors should be allowed to make motions and objections,
given that such filings affect the Court and Original Plan, asking the Court to dismiss the
illegitimate creditors’ filings.560
iii.

Chubb’s Objection to the Disclosure Statement

On October 15, 2019, the Chubb Companies (“Chubb”) filed an objection the Original Plan
and disclosure statement.561 Chubb asserted several reasons for their objection to the disclosure
statement, including: (i) the Plan was “patently unconfirmable”; (ii) both the disclosure statement
and the Original Plan attempted to improperly modify the insurance program’s terms, and the
Original plan asserted improper assignment of the insurance; (iii) the Original Plan was
inconsistent with the provisions relating to the insurance programs; (iv) both the Original Plan and
disclosure statement misconstrued the coverage, and any dispute relating to it was to be settled
under the terms of the coverage; and (v) both documents failed to provide information about
Workers’ Compensation claims and direct actions, which were to continue to be administered in
the ordinary course of business according to the applicable law.562 Chubb then requested the Court
to either require Insys to modify the issues in the disclosure statement, or deny the request for to
approve the disclosure statement and grant related relief.563
iv.

Limited Objection of the Disclosure Statement by the SEC

On October 24, 2019, the Securities and Exchange Commission (“SEC”), filed a limited
objection against the disclosure statement stating: (i) it lacked adequate information to support the
exculpation of the provisions in the Original Plan under Bankruptcy Code section 1125(b); (ii) the
Original Plan appeared to discharge any liability of a non-debtor party, contradicting Bankruptcy
section 524(e).564 Bankruptcy Code section 1125(b) provides that a debtor may not solicit an
acceptance or rejection from a claim or interest holder with respect to such claim or interest, unless
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the claim or interest holder received a written disclosure statement, and after notice and hearing,
the Court approved the disclosure statement, stating it had sufficient information.565
First, the SEC alleged that the Original Plan’s disclosure statement failed to provide
sufficient information, and contained conflicting information and the Third Party Releases.566 A
Third Party Release was a provision in the Original Plan that sought to release and permanently
enjoin actions against non-debtor third parties (“Third Party Release”).567 The disclosure
statement failed to provide a Third-Party Release definition, and failed to provide who was affected
by it.568 The SEC concluded that, without a definition or identification of parties enjoined, a holder
of a claim could not have known if they were enjoined by the litigation against third parties.569
Second, the SEC addressed how the Third Party Releases violated Bankruptcy Code section
524(e), as well as other applicable law, as 524(e) states that when a debtor’s debt is discharged,
the discharge does not affect the liability of any other entity on such debt, or the property of any
other entity on such debt.570 Third, the SEC claimed that the shareholders were entitled to
affirmatively opt out, but were deemed to reject and not given voting rights.571 The SEC asserted
that Insys did not state whether the parties who did not receive a solicitation package, whether they
were not entitled to or they were unreachable, were to be omitted from the Third Party Release,
stating that Insys should not rely on silence as a manifestation of consent to the Third Party
Release.572
v.

MDL Plaintiffs’ Objection to the Approval of the Disclosure Statement

On November 1, 2019, the MDL Plaintiffs assert that the Disclosure statement was
insufficient because: (i) it described the plan that was “patently unconfirmable”; and (2) it did not
provide adequate information to inform a holder of a claim to make an informed vote.573 The MDL
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Docket 810 at 6. ; See 11 U.S.C. § 1125(b) and 11 U.S.C. § 1125(a)(1): Adequate information enables one with a
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Objection of the MDL Plaintiffs to Approval of Disclosure Statement for Joint Chapter 11 Plan of Liquidation
Proposed Docket 835 at 17.
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Plaintiffs claimed that the government creditors were misled by the information in the disclosure
statement.574 Further, the MDL Plaintiffs claimed that the Original Plan impermissibly split
similar claims to gerrymander a favorable vote.575 MDL Plaintiffs claimed the disclosure
statement failed to provide approximate values for Class 7 for the estate claims and causes of
action, or the recovery analysis.576 MDL Plaintiffs supported their claim that the disclosure
statement failed to provide adequate information, but listing various other discrepancies.577
vi.

Florida’s Objection to the Disclosure Statement

On November 11, 2019, the State of Florida (“Florida”) objected to the disclosure
statement because: (i) it failed to provide adequate information under Bankruptcy Code section
1125(b), that allowed creditors to make an informed voting decision as to whether to accept or
reject the Original Plan; and (ii) the description of the Original Plan was “so patently
unconfirmable,” that voting would have wasted time.578 The State of New York filed a joinder to
this objection.579 Florida stated that the disclosure statement inadequately described key
considerations, including failing to sufficiently describe how the creditors’ distributions were to
be funded, by anything other than the limited funds of Insys at that time.580 Similar to the MDL
Plaintiffs, Florida asserted that the Class allocations gerrymandered a favorable.581 Due to these
assertions, Florida requested the Court to enter an order that denied Insys’s disclosure statement
and that the Court grant any proper relief.582
vii.

Securities Lead Plaintiffs’ Objection to the Disclosure Statement

On November 4, 2019, Clark Miller, who the court appointed as lead plaintiff in Di Donato
v. Insys Therapeutics, Inc., (“Secured Litigation”), pending in the U.S. District Court for the
District of Arizona, (“Arizona Court”) submitted an objection on behalf of himself and the
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Securities Litigation’s certified class.583 Miller stated that the disclosure statement failed to
provide a proper Third Party Release because it attempted to waive the certified class’s claims
against any non-debtor defendants, as those might have been their only way to recover.584 Next,
Miller stated that the Original Plan deemed the certified class as unable to vote, and would not
have receive the disclosure statement, leaving them unaware of their ability to opt out of the Third
Party Release.585 Miller stated that it was impossible to understand the Third Party Release’s scope
without distributing of the plan supplement, which was not to be filed for some time.586 Which
would leave certified class unknowing of their stance in the Third Party Release, and if included,
leaving them without the ability to opt out of it.587 Miller further stated that the Court lacked the
jurisdiction to release the non-debtor’s liabilities.588 For these reasons, Miller objected to the
approval of the Disclosure Statement for the Original Plan.
viii.

U.S.’s Objection to the Disclosure Statement

On November 4, 2019, the U.S. objected to the Original Plan and disclosure statement
asserting that the Original Plan failed to comply with Bankruptcy Code section 1129 because the
classifications and distributions were unfair for general unsecured claims in Classes 3-7.589 The
U.S. stated that Classes 4-5 were to receive “significantly more,” than the government in Classes
6-7.590 Similarly, the U.S. asserted that by Insys favored the private creditors over the public
creditors by allocating the first portion of cash to the Liquidation Trust.591 Additionally, the U.S.
alleged that Insys grouped the classes in order to obtain acceptance of the Original Plan by at least
one unsecured creditors class.592

583

Objection of Securities Lead Plaintiff to Approval of Disclosure Statement for Joint Chapter 11 Plan of Liquidation.
Docket 843 at 1.; see also Di Donato v. Insys Therapeutics, Inc., et al., Case No. CV-16-00302-PHX-NVW
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590

Id. at 9.

591

Id. at 9-10.

592

Id. at 10.

73

Next, the U.S. alleged that the disclosure statement lacked adequate information by failing
to: (i) use evidence to support the estimated claim amounts highlighted in the Plan Settlement; (ii)
to show an analysis of the distribution scheme under the Plan Settlement; (iii) prove that the
creditors were being paid more from the chapter 11 proceedings than if converted to chapter 7
cases; and (iv) provide an estimate of the Estate Value Distribution, including potential and
expected recoveries from the Preference and Indemnity Proceeds.593 Lastly, the U.S. explained
that without adequate information, the creditors could not determine their actual recoveries under
the suggested Plan Settlement.594 Thus, the U.S. requested the Court to reject the Original Plan
and disclosure statement, requiring Insys and the Creditors’ Committee to use more time and
resources to provide adequate information on these issues.595
ix.

U.S. Trustee’s Objection to Insys’s Motion for Entry of an Order

On November 4, 2019, the United States Trustee (“U.S. Trustee”) objected to Insys’s
motion for entry of an order to approve the proposed disclosure statement.596 U.S. Trustee objected
to Insys proposed order and notices because Bankruptcy Rule 3017(d) was not satisfied, which
permitted the Court to render another order with respect to one or more impaired classes giving
Insys the opportunity to provide instructions on how to access the disclosure statement and
Original Plan through their website or USB copy.597 Under Bankruptcy Rule 3017(d), U.S. Trustee
stated that Insys should be required to provide the copies to all creditors and interests holders.598
Additionally, U.S. Trustee objected to Exhibit 1, claiming that the notice of a hearing contained
contradictory language about ability to opt-out of Third Party Releases, and also objected to
Exhibit 3-1, stating the notice of non-voting status for Classes 10-12 and the election to opt-out
form, were for Classes 10-12 who were not to receive the forms directly, rendering them unable
to consider giving any release.599
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Next, U.S. Trustee claimed that the disclosure statement failed to provide adequate
information allowing creditors to make informed judgments over the Original Plan relating to the
amount they have received in chapter 7.600 Similarly, U.S. Trustee asserted that the disclosure
statement failed to describe injunction and Third Party Release provisions, which violated
Bankruptcy Rule 3016(c).601 3016(c) states both the plan and he disclosure statement must clearly
describe all acts enjoined and any entities subject to the injunction.602 U.S. Trustee claimed that
the Original Plan and disclosure statement failed to provide such language, violating 3016(c).603
Due to the objections stated above, the U.S. Trustee requested the Court to deny the order for
approval, and grant appropriate relief.604
j. The Amended Plans
Insys amended the Original Plan twice and modified the second amended plan before it
could be confirmed. The first amendment changed the Original Plan significantly due to
unresolved issues between Insys and various Creditors and implemented changes that were agreed
upon by Insys and the SMT Group Representatives.605 The second amended plan described the
Distributions to be made to each Class in greater detail.
i.

First Amended Plan

On November 14, 2019, Insys filed the First Amended Plan (“First Amended Plan”) along
with the corresponding disclosure statement.606 After filing the Original Plan, Insys, the Creditors’
Committee, and the SMT Group Representatives negotiated some issues regarding the Claims
Analysis Protocol.607 After a few weeks of negotiating, the parties mutually agreed to appointing
a mediator to help resolve the Claims Analysis Protocol issues.608 In the one day meditation, on
October 23, 2019, the parties did not reach a complete agreement, but on November 8, 2019, the
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Id. at 8; citing Fed. R. Bankr. P. 3016(c).
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Id. at 11.

605
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parties came to a mutual agreement over the Claims Analysis Protocol.609 The Plan Settlement
(“Plan Settlement”) to the First Amended Plan reflected these changes, by incorporating the
compromises of controversies made between Insys, the Creditors’ Committee, and the Settling
Creditors.610 The First Amended Plan modified the initial settlement structure to a “Pro Rata
Share,” which addressed the SMT Group objections, and accounted for Insys’s failure to reach a
settlement with the SMT Group.611
Some classifications and how to calculate the “Allowed Claims,” changed the First
Amended Plan.612 The First Amended Plan provided a new Class for Class 3, the Convenience
Claims Class, which refers to any general unsecured claim against Insys that was asserted “as
liquidated or scheduled as neither contingent, disputed, or unliquidated,” while the Trade and
Other General Unsecured Claims moved to Class 4.613 The Insurance Related Claims moved to
Class 5 with TPPs, ERISA Health Plan Claimants (“ERISA”), and Ratepayers. 614 The First
Amended Plan also provided information about Classes 5 and 6’s motions for Class Proof of
Claims (“Class Proof of Claims”), which Insys, the Creditors’ Committee, and the representative
of the class agreed upon.615 The Class Proof of Claims were to be filed with the Court on the given
date as specified in the Class Claims Procedures, but the First Amended Plan did not specify a due
date.616
1. Classification of Claims & Interests
Bankruptcy Code sections 1122 and 1123(a)(1) required claims and interests to be divided
into classes for purposes of voting and distributing a plan.617 The Classifications for the First
Amended Plan were as follows:
Classes
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Docket 894 at 34, 59.
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Id.
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Id. at 60.
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Id. at 14, 76.
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Id. at 60.
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Id. at 76.

616

Id.

617

Id. at 65.

Claims and Interests

Status
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Voting Rights

Class 1
Class 2
Class 3
Class 4
Class 5
Class 6
Class 7
Class 8
Class 9
Class 10
Class 11
Class 12
Class 13

Secured Claims
Other Priority Claims
Convenience Class Claims
Trade and Other Claims
Insurance Related Claims
Hospital & NAS Monitoring Claims
DOJ Claims
SMT Group Claims
Personal Injury Claims
510(a)/(b) Subordinate Claims
510(c) Subordinate Claims
Intercompany Claims
Equity Interests

Unimpaired
Unimpaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired

No (Presumed to Accept)
No (Presumed to Accept)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No (Presumed to Reject)
No (Presumed to Reject)
No (Presumed to Reject)

Insys also modified distribution procedures for some of the classes, including the Hospital
Claims and NAS Monitoring Claims, now Class 6, which were to no longer receive distribution
from the ILT of its Pro Rata Share determined by the ILT Claims Arbiter of 31% of all Category
2 Distributions.618 Rather, Class 6 was to receive distributions by the ILT Claims Arbiter in
accordance with the “Plan Distribution Formula.”619 Additionally, the distribution for the DOJ
Claim changed, adding an “Allowance” provision, providing that the DOJ Civil Claims were
allowed $243 million.620 Rather than receiving 31.4% of all Category 3 Distributions, the DOJ
Civil Claims, except any DOJ Restitution Claim, would be distributed from the ILT in an amount
determined by “all Estate Distributable Value attributable to Class 7 calculated in accordance with
the Plan Distribution Formula.621 The same change applied to SMT Group Claims, which, instead
of receiving various percentages of different category distributions, became subject to the Estate
Distributable Value attributable to Class 8 in accordance with the Plan Distribution Formula, plus
a 10% interest in any Products Liability Insurance Proceeds and a 100% interest in any Excess
Liability Insurance Proceeds.622 In addition to shifting classes and claims around, Insys also got
rid of the PHT, consolidating it into the already established ILT.623
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Id.; See appendix Plan Distribution Formula.
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2. Objections to First Amended Plan
On November 20,2019, Williamson filed another objection to the First Amended Plan.624
Williamson stated that the First Amended Plan provisions dealing with Williamson’s treatment
failed to provide fair and equitable treatment of their secured claims pursuant to Bankruptcy Code
sections 1129(b)(1) and (2)(A).625 Similarly, they asserted that the First Amended Plan failed to
provide when they were to be paid, and failed to provide them any amount for the interest that
accrued on Insys taxes as they failed to pay them.626 Thus, Williamson requested the Court order
appropriate protection of their tax claims, and to order Insys to implement protective provisions.627
ii.

Omnibus Motions Rejecting Contracts.

Insys filed three omnibus motions to reject leases or executory contracts. The first was on
October 8, 2019, and the second was filed on October 11, 2019.628 There was a third omnibus
motion filed on December 24, 2019, which came after the Final Plan, but requested the same
relief.629 These motions were brought pursuant to Bankruptcy Code section 365(a), which allows
for debtors to assume or reject executory contracts or unexpired leases, pursuant to the Courts
approval, so long as it is not in bad faith, and benefits the estate.630 Insys also requested for the
rejection to be made effective nunc pro tunc.631 On October 18, 2019, the Court granted the first
omnibus motion to reject executory contracts; on October 29, 2019, the Court granted the second
omnibus motion to reject executory contracts; and lastly, January 10, 2020, the Court granted
Insys’s motion, deeming the contracts to be rejected, unless previously assigned by Insys, and in
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Objection to Confirmation of Plan Amended Joint Chapter 11 Plan of Liquidation Filed by Williamson County.
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all three orders, stating that any claims arising out of the rejected contracts were to be filed within
30 day of the service of their order, and in accordance with the procedures established.632
k. The Final Plan
On November 29, 2019, Insys filed the second amended plan (the “Final Plan”) and
disclosure statement (the “Final Disclosure Statement”).633 Not a lot occurred between the First
Amended and Final Plan. However, in the Final Plan Insys stated that they attempted to reach an
agreement with shareholder Yu over his objections, but their attempts were unsuccessful, claiming
that Yu’s objections were unsubstantiated legal theories to challenge the claims of creditors in
hope to recover for the shareholders, and were not so much about the information in the Final
Disclosure Statement, but rather an objection to the confirmation of the Original Plan and
Disclosure Statement.634 Additionally, the Final Plan split Class 8 into 8(a) and 8(b) and
established a solidified version of the treatment of the Claims and Interests in each Class.635
i.
Classes
Class 1
Class 2
Class 3
Class 4
Class 5
Class 6
Class 7
Class 8(a)
Class 8(b)
Class 9
Class 10
Class 11
Class 12
Class 13

Creditor Classification
Claims and Interests
Secured Claims
Other Priority Claims
Convenience Class Claims
Trade and Other Claims
Insurance Related Claims
Hospital & NAS Monitoring Claims
DOJ Claims
State Claims
Municipality/Tribe Claims
Personal Injury Claims
510(a)/(b) Subordinate Claims
510(c) Subordinate Claims
Intercompany Claims
Equity Interests

Status
Unimpaired
Unimpaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired
Impaired

Voting Rights
No (Presumed to Accept)
No (Presumed to Accept)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No (Presumed to Reject)
No (Presumed to Reject)
No (Presumed to Reject)

Order Granting Debtors’ First Omnibus Motion for an Order Authorizing the Rejection of Certain Executory
Contracts Docket 786; Order Granting Debtors’ Second Omnibus Motion for an Order Authorizing the Rejection of
Certain Executory Contracts Docket 823; Order Granting Debtors Third Omnibus Motion for an Order Authorizing
the Rejection of Certain Executory Contracts Effective Nunc Pro Tunc Docket 1083; See also Docket 294.
632
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Second Amended Joint Chapter 11 Plan of Liquidation Docket 928; Disclosure Statement for Second Amended
Joint Chapter 11 Plan of Liquidation. Docket 929
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Docket 929 at 8. See also Yu Objection Docket 719

635

Notice of Filing of Blacklines of Second Amended Plan and Second Amended Disclosure Statement. Docket 930
at 29-30.
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ii.

Treatment of the Creditors

As set out in the Amended Plan, the information below was provided in the Final Plan but
the Final Plan a more detailed list of percentage allocations that claims holders were to receive:
1. Administrative Expense Claims: were to receive an equal amount of the “Allowed
Claim,” distributed from the Claims Reserve, within 30 days following either the
Effective date, or the date which the Claim is deemed allowed, whichever came later.636
2. Priority Tax Claims: were to receive either cash in an equal amount to the Allowed
amount of the Claim from the Priority Reserve, or other treatment satisfying
Bankruptcy Code section 1129(a)(9).637
3. Class 1 Secured Claims: the legal, and equitable rights of these claimants were
unaltered by this Plan.638 Allowed Secured Claim were to receive: (i) payment in full
in accordance with Bankruptcy Code section 506(a); (ii) reinstatement of their Claim
under Bankruptcy Code section 1124; or (iii) another treatment to render them
unimpaired.639
4. Class 2 Other Priority Claims: On, or soon after the Effective Date, the holders of these
Claims were to receive: (i) full payment of their Allowed Claim; or (ii) treatment
satisfying Bankruptcy Code section 1129(a)(9).640
5. Class 3 Convenience Class Claims: were to receive equal to 10% of the cash available
on, or soon after the Effective Date, or when the Claim becomes “Allowed,” whichever
is later.641
6. Class 4 Trade and Other Claims: “In full and final satisfaction, settlement, release, and
discharge of an Allowed Trade and Other Unsecured Claim,” the Claimants were to
receive its Pro Rata Share of Class 4’s Estate Distributable, which was calculated by

636

Second Amended Joint Chapter 11 Plan of Liquidation For Solicitation. Docket 955 at 26.; See appendix for
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multiplying the Category 1 Distributions by the Private Group Distribution Percentage
for Class 4.642 Distribution of these Allowed Claims were not to come before the TUC
Class Amount Final Determination, and all Claims were to be held in a disputed claims
reserve until TUC Class Claim Final Determination.643
7. Class 5 Insurance Related Claims: “In full and final satisfaction, settlement, release,
and discharge of an Allowed Insurance Related Claim,” the ILT Claims Arbiter
determined the following allocation between the ERISA, TPP, and Ratepayers: ILT
was to Distribute the holder’s share of Class 5’s Estate Distributable Value.644 This
amount was calculated by multiplying the Category 1 Distributions by Class 5’s Private
Group Plan Distribution Percentage, pursuant to all applicable procedures.645
8. Class 6 Hospital and NAS Monitoring Claims: “In full and final satisfaction,
settlement, release, and discharge of an Allowed Hospital or NAS Monitoring Claim,”
the ILT Claims Arbiter determined the following allocation between Hospital Claims
and NAS Monitoring Claims: ILT was to distribute the share of each holder’s Estate
Distributable Value, calculated by multiplying the Category 1 Distributions by Class
6’s Private Group Plan Distribution Percentage, pursuant to applicable procedures.646
9. Class 7 DOJ Claims: “In full and final satisfaction, settlement, release, and discharge
of an Allowed DOJ Claims,” the DOJ was to receive restitution from the ILT, for any
Allowed DOJ Claim’s Class 7’s Estate Distributable Value, not including the Allowed
DOJ Restitution Claims.647 Estate Distributable Value in this Class was calculated by
multiplying the Category 2 Distribution with the Public Group Plan Distribution
Percentage.648 However, the DOJ Settlement Order required these Distribution were
not to be made until the GUC Recovery and Reallocation Threshold was met.649
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10. Class 8(a) State Claims & Class 8(b) Municipality/Tribe Claims: “In full and final
satisfaction, settlement, release, and discharge of an Allowed State and Allowed
Municipality/Tribe Claim,” were to receive restitution from the ILT and the VRT, its
Pro Rata Share of: (i) its Estate Distributable Value, calculated by multiplying the
Category 2 Distribution with Class 8(a) and (b)’s Public Group Plan Distribution
Percentage collectively; (ii) 10% of Products Liability Insurance Proceeds; and (iii)
100% interest in Products Liability Insurance Proceeds.650 These Claims were entitled
to $800,000 in Professional Fee Claims for Counsel employed in these cases.651
11. Class 9 Personal Injury Claims: “In full and final satisfaction, settlement, release, and
discharge of an Allowed Personal Injury Claim,” each Claimant was to receive its Pro
Rata Share of 90% of Products Liability Insurance Proceeds, distributed by the VRT.652
12. Class 10 510(a)/(b) Subordinate Claims: Pursuant to Bankruptcy Code section 510(a)
and (b), holders of subordinate claims were extinguished without further action by the
Court and were no longer effective.653
13. Class 11 510(c) Subordinate Claims: Pursuant to Bankruptcy Code section 510(c),
subordinate Claims were extinguished, were no longer effective, and without further
action by the Court.654
14. Class 12 Intercompany Claims: not to receive any property under the Final Plan for
such Claims, and were expunged and extinguished, without further effect.655
15. Class 13: Equity Interests: were not to receive property under the Final Plan, and as of
the Effective Date, Equity Interests were deemed to be surrendered or redeemed
without further action of the Court.656
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l. Disclosure Statement for the Second Amended Plan
On December 4, 2019, the Court entered an order approving Insys’s Final Disclosure
Statement (“Approval Order”).657 The Approval Order deemed the Final Disclosure Statement to
have adequate information pursuant to the Bankruptcy Code.658 Similarly, the Approval Order
specified that all objections filed before the Final Plan, as well as those filed at the Final Disclosure
Statement hearing, were either deemed as solved or overruled by the Final Plan.659 Further, the
Approval Order summarized all approved provisions in the Final Plan, including Voting (“Voting
Procedures”) and Solicitation Procedures (“Solicitation Procedures”).660 The Approval Order
provided the dates for both the Confirmation hearing, January 16-17, 2020, and the objection
deadline, January 6, 2020 (“Plan Objection Deadline”).661
m. Solicitation
The Approval Order also provided Solicitation and Voting Procedures for the Final Plan.662
Pursuant to Bankruptcy Rule 3019, the Solicitation Procedures required Insys to mail all required
materials to each class (“Solicitation Packages") within three business days of the entry of order
(“Solicitation Deadline”).663 3017(d) provides that Solicitation Packages obtained: (1) the
Approval Order, (2) the Final Plan; (3) the Final Disclosure Statement, (4) the Confirmation
Hearing Notice, (5) a Ballot to vote with, and (6) a pre-paid, pre-address return envelope.664
The Approval Order allowed Insys to distribute the Approval Order, Final Plan, and Final
Disclosure Statement in an electronic format, including CD or flash drive.665 However, it required
the ballot, Confirmation Hearing Notice, and other required materials to be in paper format.666 Any
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Order (I) Approving the Disclosure Statement and the Form and Manner of the Notice of a Hearing Thereon, (II)
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Claimant that received electronic distributions could request a paper copy from EPIQ (“Soliciting
Agent”).667 Under the Solicitation Procedures, the “Voting Classes,” could turn in both paper and
electronic.668 The Voting Classes were those Impaired by the Final Plan, and allowed to vote to
accept it or reject it.669 If Voting Class member could not be reached by mail, Insys was excused
from mailing the Solicitation Packages, unless an accurate address was provided to Insys was
before the Voting Deadline (“Voting Deadline”), on January 6, 2020.670
Additionally, the Approval Order stated that Voting Classes were not entitled to vote if the
claim: (1) was no greater than $0.00; (2) was disallowed as of the Voting Record Date; (3) was not
scheduled, or was scheduled but deemed as contingent, unliquidated, or disputed, and was not
timely filed according to the “Bar Date Order”; or (4) was subject to objection or request for
estimation before the “Claim Dispute Deadline.”671 However, Classes 8(a) and (b) Claims were
able to vote even if they were scheduled as contingent, unliquidated, or disputed.672 "Non-Voting
Classes,” were unimpaired Classes and subordinate classes, and were to receive: (1) the
Confirmation Hearing Notice, (2) the Non-Voting Class Notice, and (3) the Opt Out Election Form
(“Opt Out Election Form”) allowing the classes to opt of releases set out in the Final Plan.673 The
deadline to opt out of certain Third Party Release provisions in the Final Plan was January 6, 2020
(“Opt Out Deadline”).674
Lastly, Insys was required to distribute copies of the Final Plan or Disclosure Statement to
any party that held an executory contract or unexpired lease, and whose claim was not allowed,
filed, or scheduled.675 The Final Plan deemed each of the counterparties to be assumed and
assigned to the ILT, thus requiring them to receive an Assumption and Assignment notice by the
Solicitation Date.676
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i.

Tabulation Procedures

When a ballot was casted more than one time for the same claim, the last ballot received
was deemed to reflect the voter’s intention.677 Any ballot that did not clearly indicate acceptance
or rejection of the Final Plan was not counted.678 Similarly, any Ballot or Class Ballot that was
received after the Voting Deadline, illegible, contained insufficient information, was casted by a
Non-Voting Class Claim, did not have a signature, or transmitted by unapproved means, were not
counted in the vote.679 Any party with multiple claims against Insys was allowed one vote total
for all claims.680 Any Voting Class that did not render valid votes was deemed to accept the Final
Plan.681 If a Voting Class Claim was transferred, the transferor of the claim was entitled to vote
so long as they filed documentation with the Court within 21 days prior to the Voting Record Date,
and no timely objection was made by the transferor.682 The Soliciting Agent was allowed, but not
required, to contact any party that submitted incomplete or otherwise deficient ballots to cure the
deficiencies.683
n. Voting Results
On January 13, 2020, EPIQ filed a declaration certifying the validity of the ballots on the
Final Plan.684 The Classes where all claims accepted the Final Plan were: (1) Class 3 Convenience
Claims; (2) Class 5 Insurance Related Claims; (3) Class 6 Hospital and NAS Monitoring Claims;
(4) Class 8(a) State Claims; and (5) Class 9 Personal Injury Claims.685 Class 4 Trade and other
Unsecured Claims accepted 77.54% or 11 claims amounted to $2,473,659.27, and rejected 9 of
the claims amounting to $716,474.74.686 Class 8(b) Municipality/Tribe Claims accepted 97.74%
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or 1,722 claims amounting to $1,1771.00, rejecting 41 Claims amounting to $41.00.687 Class 7
DOJ Claims did not submit votes to accept or reject the Final Plan, and were therefore deemed to
accept the Final Plan pursuant to section 3.3 of the Final Plan.688 As the Final Plan stated, Class
1, Secured Claims, and Class 2, Other Priority Claims, were deemed to accept the plan under
Bankruptcy Code section 1126(f).689 Due to acceptance from one impaired voting class by the
majorities required in the Final Plan, Bankruptcy Code section 1129(a)(10) was satisfied.690
i.

Extending Time for Approval

On January 3, 2020, Insys requested the Court extend the exclusivity period by which Insys
could file a chapter 11 plan and solicit acceptances of such plan.691 The Court granted this request
on January 22, 2020, permitting Insys through and until April 27, 2020.692
o. Objections to Confirmation of the Final Plan
i.

Limited Objection of Securities Lead Plaintiff

On January 6, 2020, Securities Lead Plaintiff, Clark Miller, filed a limited objection to
Confirmation of the Final Plan. The limited objection requested the Confirmation Order clarify:
(1) clarify that the Third-Party Release did not impact the certified class against the non-debtor
defendants;”693 (2) Miller was permitted to pursue the Class Claims against Insys for available
insurance proceeds;694 (3) that confirmation of the Final Plan did not modify or expand the rights
of any party relating to the D&O Policies;695 and (4) the VRT and the ILT were to preserve
evidence that was relevant to the Securities Litigation until it concluded.696
687
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ii.

Limited Objection of the SEC

On January 6, 2020, the SEC filed an objection to the Final Plan regarding non-debtor third
party releases.697 The SEC argued that the releases violated Bankruptcy Code section 524(e).698
Moreover, the SEC stressed the significance of non-debtor third party releases, arguing that such
releases enabled non-debtors to benefit from Insys’s bankruptcy by allowing the non-debtors a
release for their own past misconduct that violated federal securities law or breached state law
fiduciary duties.699 Therefore, the SEC believed that the release and exculpation provisions should
be removed from the Final Plan so that the Class 13, Equity Interests, could be removed from the
releases or be required to “opt in”, instead of Class 13 having to affirmatively opt out.700
Pursuant to Bankruptcy Code section 524(e), the SEC believed that the Final Plan’s Third
Party Release was not consensual, therefore violating the standard requiring it to be a consensual
release.701 Moreover, the SEC argued that the Third Party Release violated Bankruptcy Code
1123(e)(4) by creating the possibility of treating of similarly situated class members disparately.702
Thus, the SEC requested that the Class 13, Equity Interests, be removed from the Third Party
Release and injunction, or they be required to opt in instead of having to opt out.703
iii.

The U.S. Trustee’s Objection

On January 6, 2020 the U.S. Trustee, like the SEC, filed an objection to the Final Plan
requiring the Equity Interest holder to opt-out of such releases.704 The U.S. Trustee argued that
(1) Third Party Release require affirmative consent; (2) Insys did not meet the standards for nonconsensual Third Party Release, and (3) pursuant to Bankruptcy Code Section 503(b)(3)(D), the

696

Docket 1064 at 10.

697
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SMT Group failed to demonstrate that the release made substantial contribution to outcome.705
For those three reasons, the U.S. Trustee requested the Court deny confirmation of the Final Plan
or grant appropriate relief.706
iv.

Chubb’s Objection

On January 9, 2020, the Chubb filed an objection to the Final Plan’s treatment of Insurance
Programs.707 Chubb stated the insurance programs were improperly assigned by the Final Plan,
arguing that the Insurance Programs could not be assigned without prior written consent from
Chubb, and stating Chubb was not requested to and did not give consent.708 Furthermore, Chubb
objected to the ILT and the VRT receiving benefits of the programs, while avoiding liability for
failing to comply with the provisions of the policies and applicable non-bankruptcy law.709
Further, Chubb claimed the Final Plan disregarded coverage defenses, arguing that disputes related
to such defenses should be adjudicated and determined under the original terms of the Insurance
Programs along with applicable law.710 Similarly, Chubb asserted the Final Plan failed to provide
the process for the handling of WC Policy Claims and direct action claims.711 Chubb mentioned
the negotiating and requesting appropriate and necessary language in the Original Plan that would
have resolved this objection, but they failed to reach an agreement.712 Finally, Chubb requested
the Court either (a) deny confirmation of the Final Plan, or (b) modify it to reflect their objections,
and to grant appropriate relief.713 On January 14, 2020, Insys responded to the objections by filing
a modification to the Final Plan.714
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p. Final Plan Modification
As stated above, on January 14, 2019 Insys filed a modification to the Final Plan (“Final
Plan Modification”).715 In the Confirmation Order of the Final Plan, filed January 16, 2019, the
Court stated that “modification made to the Final Amended Plan, (i) complied with Bankruptcy
Code section 1127 and Bankruptcy Rule 3019, (ii) did not adversely affect the treatment Allowed
Claims holders, and (iii) did not require re-solicitation of votes with respect to the Final Plan.”716
The Final Plan was deemed to be accepted by the previous vote, and the modifications made did
not affect the previous acceptance.717
Similarly, the Final Plan Modification added more categories for Allowed DOJ Claims,
including DOJ Civil Claims, DOJ Forfeiture Claims, and DOJ Restitution Claims that included
DOJ Residual Restitution Claims.718 DOJ forfeiture Claim was DOJ’s Claim in the amount of
$30,002,000.00 pursuant to the June 4, 2029 plea agreement between the U.S. Attorney for the
District of Massachusetts (“MA District Court”) and Insys Pharma, Inc., and relating to the
deferred prosecution agreement between Insys and the DOJ.719
DOJ Residual Restitution Claims related to, or made on behalf of any creditor of Insys that
(1) failed to file a proof of claim in these cases by the Bar Date, (2) that was not listed to have
contingent, unliquidated, or disputed scheduled claims as set forth in the schedules, and (3) was
not part of any class claim.720 These claims were only for criminal restitution claims that were not
duplicative of the claims already made for these cases.721 DOJ Restitution Claims were any Claims
filed by the DOJ seeking restitution pursuant to a final order awarding restitution in the MA District
Court in U.S. v. Insys Pharma, Inc., pursuant to the June 4, 2019 plea agreement between the U.S.
Attorney for the District of Massachusetts (“MA District Court”) and Insys Pharma, Inc.
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VIII.

Confirmation

On January 16, 2020, the Court entered its order confirming the Final Plan under
Bankruptcy Code section 1129 (“Confirmation Order”).722 The Final Plan’s acceptance was still
applicable after the Final Plan modification, and thus, the Final Plan and applicable documents did
not need to be re-solicited.723 The Final Plan went in to effect on February 20, 2020.724
a. Solicitation of the Final Plan
The Court found that Solicitation Packages transmission complied with Bankruptcy Rules
3017 and 3018, Local Rules, and the Final Disclosure Statement.725 The Voting Classes received
adequate ballots, the period for voting was reasonable, and all other procedures were satisfied
under the Final Plan.726 The Solicitation Packages were adequate, and sufficiently provided a
notice of the Confirmation Hearing, as well as adequate notice for the filing and serving of
objections to the Confirmation.727
b. Voting
The Voting Classes were served the Solicitation Packages within a reasonable time to make
a sufficiently informed vote to accept or reject the Final Plan.728 Again, under Bankruptcy Code
section 1126(f) and 1126(g), Insys was not required to serve the Non-Voting Classes, including
the unimpaired classes, and the fully impaired Subordinate classes as these Classes were deemed
to accept or reject the plan before the Solicitation.729 Solicitation Packages were sufficient to
provide notice of the Confirmation Hearing, including when the objection to the confirmation
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deadline was.730 The Court approved the method of vote tabulation, stating that it was consistent
with the Disclosure Statement Order.731
c. Plan Supplement
The Court then approved the Plan Supplements that Insys filed on December 30, 2019, and
January 6, 2020.732 All materials in the Plan Supplement provided notice of all documents therein
and were proper under all applicable rules, requiring no further notice.733
d. Liquidating Trustee
The Court approved the use of Liquidating Trustee by mutual agreement of Insys, the
Creditors’ Committee, and the SMT Group Representatives as provided in section 5.6 of the Final
Plan.734 They mutually appointed Mr. Carmin Reiss as the Liquidating Trustee for the VRT, and
William Henrich as the Liquidating Trustee for the ILT.735
e. Compliance with Bankruptcy Rule 3016
The Court stated that the Final Plan satisfied Bankruptcy Rule 3016(a) by being dated and
identifying Insys as proponents.736 Similarly, the Court stated that it met Bankruptcy Rule 3016(b)
by appropriately filing the Disclosure Statement and Final Plan with the Court, and lastly, the Final
Plan complied with 3016(c) the release and injunction provisions were bolded and set out in ,
conspicuous language.737
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f. Classification of Claims
The Court approved the Classification of Claims, stating that grouping was valid for
business, factual, and legal reasons, satisfying the applicable sections of the Bankruptcy Code.738
The unimpaired classes were set out by meaning of Bankruptcy Code section 1124, which thus
satisfied 1123(a)(2).739 The Final Plan satisfied Bankruptcy Code section 1123(a)(3), providing
equal treatment for each claim or interests in each Class, unless agreed otherwise.740
g. Implementation
Pursuant to Bankruptcy Code section 1123(a)(5), all documents filed relating to the Final
Plan provided an adequate means for its implementation, including: (1) establishing the
Liquidating Trusts and appointing the Liquidating Trustees to administer the Final Plan; (2)
appointing the Liquidating Trustee for the VRT to administer the Final Plan, (3) appointing the
VRT Claims Administrator and establishing the VRT to administer the Personal Injury Claims;
(4) appointing the ILT Board and the VRT Board; (5) substantive consolidation of Insys for
procedural reasons; (6) transferring of assets to the Trusts; (7) establishing procedures for class
claims; and (8) funding the Trust Operating Reserves.741
h. Non-Voting Equity Securities
New securities were issued under the Final Plan, facilitating Insys’s winding up and
dissolution.742 Complying Bankruptcy Code section 1123(a)(6), these new securities were issued
as Parent Equity Interest to the ILT, allowing the ILT Liquidating Trustee to control Insys.743
i. Assumption and Rejection of Contracts
Bankruptcy Code sections 365 and 1123(b)(2) were satisfied by the Final Plan , providing
all contracts and leases left unresolved on the Effective Date were deemed to be rejected unless:
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(1) listed in the scheduled Assumed and Assigned Contracts, or (2) a motion was pending on the
Effective Date to assume, reject, or assign such contract.744
j. Injunctions, Releases, & Exculpation
The Court approved the releases, exculpations, and injunctions in the Final Plan.745
Bankruptcy Code sections 105(a) and 1123(b) permits the issuance of injunctions and approvals
of releases, exculpations, and injunctions in the Final Plan.746 Further the Court stated that the
releases included in the Final Plan were key components and were a valid business decision.747
i.

Third Party Releases

The Court approved the Third Party Releases, deeming them essential to the Final Pan,
thus approving such releases as they were agreed to by Insys, the Creditors’ Committee, the SMT
Group Representatives had agreed to them as they were narrowly tailored to the Final Plan. 748
k. 9019 Settlement
Pursuant to Bankruptcy Rule 9019, factors such as duration of litigation, probability of
success, and complexity of the cases were determined to weigh in favor of resolving the disputes
as set forth in the Final Plan.749 The Court stated that Insys reached its burden of proving that the
Plan Settlement and treatment of the Classes was fair and in the best interest all parties.750
l. Objections
The Court over ruled all were overruled on the merits by the Confirmation order, that were
not withdrawn, waived, or deferred, and all reservations of rights pertaining the Confirmation of
the Final Plan, other than those withdrawn with prejudice prior to or at the Confirmation
Hearing.751 The Confirmation Order constituted the Court’s approval of the Plan Settlement,
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including that: (1) it was in the best interests of Insys and the Estates, as well as their respective
property and stake holders; (2) it was fair, equitable, and reasonable.752
IX.

Post-Confirmation

After Confirmation Order was entered, there were still matters to be resolved before
transfers could occur and Insys could begin to windup business. This section details the various
motions and orders filed after confirmation of the Final Plan.
a. Assumption and Assignments
On January 23, 2020, Insys filed a stipulation between them and Hikma and IMA North
America regarding the assumption and assignment of a contract for the purchase order of Nasal
Peelable Tooling (the “NPT Contract”).753 Although the Bankruptcy Court already approved the
assumption and assignment of certain contracts regarding the transaction between these parties on
August 22, 2019, the NPT Contract was not included.754 The Court approved this acquisition on
January 24, 2020.755 On February 19, 2020, the Court entered an order approving a stipulation
between Insys and Senzer Limited regarding the assumption and assignment of certain contracts.756
b. Payment of Administrative Claims
On January 28, 2020, the Court approved Ascent Health Services’ motion for allowance
and payment of administrative claims pursuant to Bankruptcy Code section 503(b)(1)(A).757 On
March 17, 2020, the Court approved another motion by Ascent Health Services regarding the
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payment of administrative claims.758 The parties filed a stipulation providing that Insys had until
April 20, 2020 to respond to Ascent’s motion.759 Furthermore, the stipulation gave Insys 10 days
to pay any and all claims not in dispute to Ascent.760 For claims in dispute, a hearing was to be
held.761 The stipulation allowed either party to extend any deadline established by the agreement,
to which Insys took advantage of on April 20, 2020.762 Insys requested that the Court would extend
this deadline through December 17, 2020.763 The Court granted this order on May 1, 2020.764
On March 9, 2020, AlphaScrip, Inc. filed a motion requesting authority to pay an
Administrative Expense Claim for $53,102.95, plus attorneys’ fees, indemnification, and other
costs as recoverable under the ICO Agreement and applicable law for unpaid post-petition services
provided to Insys.765 Before Insys filed for bankruptcy, they entered into an agreement with ICO,
agreeing to provide ICO with discount vouchers for prescription medications and to facilitate
payments to pharmacies for the vouchers.766 In return, ICO would make payments to Insys equal
to invoiced amounts within 10 days of such invoices.767 As of the Petition Date, Insys had a
security deposit for $324,000.00 relating to the ICO Agreement.768 As of the date of rejection,
Insys still owed $53,102.95, net of the deposit, for fees incurred under terms the ICO Agreement,
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after the Petition Date.769 On April 16, 2020, the Court entered an order granting AlphaScrip, Inc.
its motion, requiring Insys to pay this claim within five business days after entry of the order.770
On June 3, 2020, the Liquidating Trustee filed a stipulation regarding administrative claims
of Bessemer Trust Company (“Bessemer”) totaling $458,000.771 Pursuant to Bankruptcy Code
section 503, the stipulation provided Bessemer an allowed claim of $230,000 to be paid within 10
days of this agreement.772 In addition, Bessemer received an allowed general unsecured claim
(placing Bessemer in Class 4 of the Plan) for $230,000.773 On July 9, 2020, Bessemer transferred
their claims against Insys to Contrarion Funds, LLC.774
c. Late Proof of Claims
On May 12, 2020, Richard Landucci, Paul Lara, Kimberlee Kossup, William Thornton,
and Andrew Lasky (the “Movants”) filed a motion requesting the Court to allow them to file a late
proof of claim.775 The bar date order required any claim arising before the Petition Date to be filed
on September 16, 2019.776 However, the Movants did not receive proper notice as they were
unknown personal injury claimants.777 Bankruptcy Rule 9006(b)(1) provides an exception to bar
dates if “failure to act was the result of excusable neglect,” which each claimant must prove for
themselves.778 The Court granted leave to file proofs of claim on each claimants behalf no later
than July 31, 2020.779
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d. Orders Extending Time
On January 3, 2020, prior to confirmation, Insys requested the Court extend the period
within which Insys could remove actions under Bankruptcy Code section 1452 and Bankruptcy
Rule 9006(b) and 9027 by 120 days, allowing Insys through May 5, 2020.780 On January 22, 2020,
the Court granted Insys’s request.781
On February 14, 2020, Insys filed a motion to extend the ILT Claim Arbiter’s time to
determining the allocation of claims under the Final Plan.782 This motion was filed as a stipulation
between Insys and the Creditors’ Committee and Class Representatives.783 Rather than giving the
ILT Claims Arbiter “60 days following the Effective Date,” as requested in section 5.7(i) of the
final Plan, the stipulation provided that ILT Claims Arbiter was to begin responsibilities on June
1, 2020, or a date that is later agreed to by the Class Representatives.784 The Court approved this
order that same day.785 On June 19, 2020, the date for ILT Claims Arbiter to begin was set for
September 1, 2020 and on June 22, 2020, the Court approved it.786 However, another stipulation
was filed further modifying the date to be between September 1, 2020, and November 1, 2020,
only affecting the Hospital Class Representative and NAS Monitoring Class Representative by
allowing them time to complete arbitration required by the Final Plan.787 The Court approved this
modification as it pertains to the Hospital Class Representative and NAS Monitoring Class
Representative on September 21, 2020.788
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On June 2, 2020, the Liquidating Trustee filed a motion extending the claim’s objection
deadline through February 16, 2021.789 In about three and a half months, over 4,200 claims totaling
about $12 billion were filed.790 The Liquidating Trustee claimed that he and his professionals
were working diligently to set up various processes for reconciling and reviewing claims,
especially with certain Administrative Claims, along with juggling tax issues and returns and the
wind down of Insys’s 401K plan.791 On top of the volume of work, the Coronavirus pandemic had
shut down much of society and getting work done in and of itself was a difficult task at this time.792
Due to these issues, the Liquidating Trustee knew he would run out of time to handle it all.793 On
June 11, 2020, the Court granted the Liquidating Trustee’s motion extending the claim’s objection
deadline through February 16, 2021.794
On November 9, 2020, the Liquidating Trustee filed a motion requesting an extension for
the time to object to administrative claims by six more months, through June 17, 2021.795 The
Court granted the motion on November 25, 2020.796 On December 22, 2020, the Liquidating
Trustee, having filed nine omnibus objection claims and expunged over 700 claims, filed a motion
requesting the Court to extend the objection deadline through August 31, 2021.797 The Court
granted the motion on January 13, 2021, extending the claims objection deadline through August
31, 2021.798 Another motion to extend the time to object to claims was filed on May 3, 2021. 799
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This motion, however, was for all claims, meaning administrative ones also.800 The Court granted
this motion on May 14, 2021, extending all claims through January 28, 2022.801
The final motion requesting the Court to extend the time to object to all claims was filed
on November 19, 2021.802 Realizing the Liquidating Trustee needed much more time than just a
couple month extension, the motion requested the Court to extend the time an entire year for all
claims, through January 28, 2023.803 The Court granted this motion in its entirety on December
12, 2021.804
e. Classification of Claims
On January 17, 2020, the Court entered an order approving a stipulation concerning the
classification of claims of Steve Meyer and Pierre Lapalme. 805 The Final Plan classified Meyer
and Lapalme in Class 11, 501(c) Subordinated Claims, but they argued their claims should be
classified in Class 4, Trade and Other Unsecured Claims.806 On February 19, 2020, the Court
approved a stipulation between Insys and Pharmaceutical Research Associates, Inc. classifying
their claims in Class 4.807

800

Docket 1640 at 2-4.

801

Order Granting Motion of the Liquidating Trustee of the Insys Liquidating Trust for Entry of an Order Extending
the Time to Object to All Claims. Docket 1661 at 2.
802

Motion of the Liquidating Trustee of the Insys Liquidating Trust for Entry of an Order Extending the Time to
Object to All Claims. Docket 1772 at 1.
803

Id. at 5-6.

804

Order Granting Motion of the Liquidating Trustee of the Insys Liquidating Trust for Entry of an Order Extending
the Time to Object to All Claims. Docket 1775 at 2.
805

Order Approving Stipulation Concerning Classification of Claims of Steve Meyer and Pierre Lapalme for
Confirmation and Voting Purposes. Docket 1125.
806

Certification of Counsel Regarding Order Approving Stipulation Concerning Classification of Claims of Steven
Meyer and Pierre Lapalme for Confirmation and Voting Purposes. Docket 1123 at 5.
807

Order Approving Stipulation and Agreement Between Debtors and Pharmaceutical Research Associates
Regarding Treatment of Certain Contracts. Docket 1206.

99

f. Asset Transfers
On December 13, 2019, Insys filed a motion requesting the Court’s approval to expedite
procedures for the De Minimis assets and to expedite an exclusive auction and sales agreement.808
In this motion, Insys requested the Court’s approval over the sale and transfer of any De Minimis
Asset, and if Insys was unable to find a buyer for such assets, they requested to abandon the
property.809 Furthermore, Insys requested permission to pay any fees incurred with the sale,
transfer, or abandonment of the De Minimis assets and with the Creditors’ Committee’s consent,
Insys requested to enter into an exclusive auction and sales agreement with their chosen
liquidator.810 If property was not sold, Insys requested to abandon such property, as provided in
the sales agreement regarding the location of De Minimis assets, any personal property left on the
premises would be deemed abandoned as of December 31, 2019.811 The Court granted this motion
on December 30, 2019.812 On February 3, 2020, Insys filed a motion reporting on the De Minimis
asset transfers for the period from between December 30, 2019 and January 31, 2020.813
g. Orders Regarding Plan Administration
On February 19, 2021, the Liquidating Trustee filed a motion requesting the Court to
authorize a third party’s work on initial disclosure requirements under section 3.08 of the ILT
Agreement.814 The issue was that the Liquidating Trustee had a cap of $250,000 to which he was
he spend on fulfilling the disclosure requirements under the Final Plan.815 Meanwhile, the New
York Attorney General’s office was already in the middle of making documents it had in its
possession public.816 This endeavor included removing documents that contained sensitive
808

Motion of Debtors Pursuant to 11 U.S.C. §§ 105(a), 363, and 554 and Fed. R. Bank. P. 2002 for Approval of (I)
Procedures for the Expedited Sale, Transfer or Abandonment of De Minimis Assets, and (II) Entry into an Exclusive
Auction and Sales Agreement. Docket 985 at 1.
809

Id. at 2.

810

Id.

811

Id. at 5-6.

812

Order for Approval of (I) Procedures for the Expedited Sale, Transfer, or Abandonment of De Minimis Assets,
and (II) Entry Into An Exclusive Auction and Sales Agreement. Docket 1041.
Debtor’s Report of De Minimis Asset Transfers for the Period From December 30, 2019, Through and Including
January 31, 2020. Docket 1161.
813

814

Motion of the Liquidating Trustee of the Insys Liquidation Trust for Authorization to Permit Third Party to
Perform Initial Disclosure Requirements Under Section 33.08(b) of the ILT Agreement. Docket 1495 at 3-8.
815

Id. at 3.

816

Id. at 4.
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information or that were potentially privileged.817 The Liquidating Trustee requested authority
from the Court to use the documents the New York Attorney General’s office had already sifted
through, and that were made public to save valuable resources and valuable time.818 On March 9,
2010, the Court granted Insys’s motion.819
On March 1, 2021, Complete Fleet Services, as the Final Plan’s Class 5 Representatives,
filed a motion for the Court’s approval of the allocation plan.820 On March 30, 2021, Class 5 TPP
Claimants filed an objection, stating that the allocation plan lacked detail and analysis, and failed
to allocate any real value to Class 5.821 Most importantly, TPP Claimants objected to the
professional fees being paid by the Final Plan, leaving almost no recovery for the class members.822
In their reply, the Class 5 Representative stated that TPP Claimants did not have standing
to object, under Bankruptcy Code section 1109(b), which states that a claimant must have a
“significant stake” to have standing for objections.823 In addition, the Class 5 Representative
argued that TPP Claimants could not change an arbitration award by objecting to them.824 Finally,
at a telephone hearing on April 13, 2021, the Court sustained TPP Claimants objection and denied
the Class 5 Representative’s motion.825 The Court ordered the parties to confer and submit a form
of order incorporating the Court’s ruling under certification of counsel.826

817

Docket 1495 at 4.

818

Id. at 5.

819

Order Authorizing Third Party to Perform Initial Disclosure Requirements Under Section 3.08(b) of the ILT
Agreement. Docket 1540.
820

Motion to Approve the Insurance Ratepayer Class Claimants for the Entry of an Order (A) Approving the
Insurance Ratepayers’ Allocation Plan, (B) Approving the Forms and Methods for Notifying the Class of Resolution
of the Ratepayers Claims, and (C) Granting Related Relief. Docket 1538 at 1, 5.
821

Objection to the Motion of the Insurance Ratepayer Class Claimants for the Entry of an Order (A) Approving the
Insurance Ratepayers’ Allocation Plan, (B) Approving the Forms and Methods for Notifying the Class of Resolution
of the Ratepayers Claims, and (C) Granting Related Relief. Docket 1557 at 3.
822

Id.

823

Reply in Further Support of Motion of the Insurance Ratepayer Class Claimants for the Entry of an Order (A)
Approving the Insurance Ratepayers’ Allocation Plan, (B) Approving the Forms and Methods for Notifying the
Class of Resolution of the Ratepayers Claims, and (C) Granting Related Relief. Docket 1566 at 4; citing 11 U.S.C.
§ 1109(b).
824

Id. at 5.

825

Minute Entry. Docket 1583

826

Id.
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On May 5, 2021, the trustee for the Victims Restitution Trust filed a motion to enforce the
plan injunction established in the Final Plan’s section 10.4, which bars any action against trust
assets.827 This motion was filed against a former employee, Jessica Larichuita, who faced litigation
for her role in Insys’s wrongful marketing of opioid products.828 On May 13, 2021, the Court
granted this motion, approving the injunction against Larichuita.829
h. Omnibus Objections
After the Final Plan was confirmed, the ILT Trustee and the VRT Trustee reviewed and
accepted or rejected claims brought pursuant to the assets in each given trust.
i.

ILT Omnibus Objections

Between July 24, 2020 and February 28, 2020, the ILT Trustee filed 20 omnibus objections
to claims brought under the ILT.830 The ILT Trustee filed the omnibus objections, claiming that

827

Motion to Enforce the Plan Injunction by the Trustee of the Victims Restitution Trust. Docket 1647 at 9-10.

828

Id. at 4.

829

Order Granting Motion to Enforce the Plan Injunction by the Trustee of the Victims Restitution Trust. Docket
1659.
830

First Omnibus Objection to Claims of the Trustee of the Insys Liquidation Trust to Claims. Docket 1382; Second
Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1416; Third Omnibus Objection
to Claims Third Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1417; Omnibus
Objection to Claims Fourth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket
1418; Omnibus Objection to Claims Fifth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1419; Omnibus Objection to Claims Sixth Omnibus Objection of the Trustee of the Insys
Liquidation Trust to Claims. Docket 1420; Omnibus Objection to Claims Seventh Omnibus Objection of the Trustee
of the Insys Liquidation Trust to Claims. Docket 1421; Omnibus Objection to Claims Eighth Omnibus Objection of
the Trustee of the Insys Liquidation Trust to Claims. Docket 1422; Omnibus Objection to Claims Ninth Omnibus
Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1423; Omnibus Objection to Claims Tenth
Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1589; Omnibus Objection to
Claims Eleventh Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1590; Omnibus
Objection to Claims Twelfth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket
1662; Omnibus Objection to Claims Thirteenth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1707; Omnibus Objection to Claims Fourteenth Omnibus Objection of the Trustee of the Insys
Liquidation Trust to Claims. Docket 1708; Omnibus Objection to Claims Fifteenth Omnibus Objection of the
Trustee of the Insys Liquidation Trust to Claims. Docket 1737; Omnibus Objection to Claims Sixteenth Omnibus
Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1740; Omnibus Objection to Claims
Seventeenth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1777; Omnibus
Objection to Claims Eighteenth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket
1778; Omnibus Objection to Claims Nineteenth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1804; Omnibus Objection to Claims Twentieth Omnibus Objection of the Trustee of the Insys
Liquidation Trust to Claims. Docket 1805.
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they were one of various types of claims, including: (1) late claims, 831 (2) duplicate claims; 832 (3)
claims that had insufficient information;833 (4) claims reclassified as Equity interests and changed
to Class 13 disallowed claims; 834 (5) misclassified claims; 835 (6) reduced claims;836 (7) reclassified
claims; 837 (8) amended claims; 838 and (9) claims that Insys was not deemed liable for. 839 Between
August 20, 2020 and April 8, 2022, the Court granted the first omnibus objection of the ILT
Trustee.840

831

Order Granting First Omnibus Objection of the Trustee of the Insys Liquidation Trust. Docket 1396; Order
Granting Fourteenth Omnibus Objection to Claims of the Trustee of the Insys Liquidation Trust. Docket 1716.
832

Docket 1396; Order Granting Second Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1447; Order Granting Third Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1448; Order Granting Fourth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1449; Order Granting Fifth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1450; Order Granting Sixth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1451; Order Granting Seventh Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1452; Order Granting Eighth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1453; Order Granting Ninth Omnibus Objection of the Trustee of the Insys Liquidation Trust to
Claims. Docket 1454
833

Docket 1396; Docket 1716; Order Granting Nineteenth Omnibus Objection of the Trustee of the Insys
Liquidation Trust to Claims. Docket 1813
834

Order Granting Tenth Omnibus Objection of the Trustee of The Insys Liquidation Trust to Claims. Docket 1674;
Order Granting Eleventh Omnibus Objection of the Trustee of the Insys Liquidation Trust Claims. Docket 1670;
Order Granting Twelfth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket 1704;
Order Granting Thirteenth Omnibus Objection to Claims of the Trustee of the Insys Liquidation Trust. Docket 1715
835

Order Granting Sixteenth Omnibus Objection of the Trustee of The Insys Liquidation Trust to Claims. Docket
1750; Order Granting Twentieth Omnibus Objection of the Trustee of the Insys Liquidation Trust to Claims. Docket
1814.
836

Docket 1715

837

Docket 1704; Docket 1715

838

Docket 1716; Order Granting Seventeenth Omnibus Objection of the Trustee of The Insys Liquidation Trust to
Claims. Docket 1789; Order Granting Eighteenth Omnibus Objection of the Trustee of the Insys Liquidation Trust
to Claims. Docket 1788; Docket 1813.
839

Docket 1715; Order Granting Sixteenth Omnibus Objection of the Trustee of The Insys Liquidation Trust to
Claims. Docket 1750; Docket 1814.
840

Docket 1396; Docket 1814.

103

ii.

VRT Omnibus Objections

On May 4, 2021, the VRT Trustee filed 5 objections to claims brought under the VRT.841
The VRT Trustee filed the omnibus objections, claiming that they were one of various types of
claims, including: (1) late filing of claims; 842 and (2) duplicate claims.843 On June 8, 2021, the
Court entered orders granting all 5 of the omnibus objections.844
X.

Adversary Proceedings

Beginning February 18, 2021, William Henrich, Liquidating trustee, under Bankruptcy
Code section 547, brought 86 preference claims against a variety of creditors for sums ranging
from $7,000 to $1 million, seeking to avoid payments made during the 90 days prior to the Petition
Date.845 Bankruptcy Code section 547(f) provides “the debtor is presumed to have been insolvent
841

First Omnibus Objection of Carmin Reiss, In Her Capacity as Trustee of the Insys Victims Restitution Trust.
Docket 1664; Second Omnibus Objection of Carmin Reiss, In Her Capacity as Trustee of the Insys Victims
Restitution Trust. Docket 1665; Third Omnibus Objection of Carmin Reiss, In Her Capacity as Trustee of the Insys
Victims Restitution Trust. Docket 1666; Fourth Omnibus Objection of Carmin Reiss, In Her Capacity as Trustee of
the Insys Victims Restitution Trust. Docket 1667; Order Granting First Omnibus Objection of Carmin Reiss, in her
Capacity as Trustee of the Insys Victims Restitution Trust. Docket 1688.
842

Docket 1688; Order Granting Second Omnibus Objection of Carmin Reiss, in her Capacity as Trustee of the
Insys Victims Restitution Trust Order Granting Third Omnibus Objection of Carmin Reiss, in her Capacity as
Trustee of the Insys Victims Restitution Trust. Docket 1689; Order Granting Fourth Omnibus Objection of Carmin
Reiss, in her Capacity as Trustee of the Insys Victims Restitution Trust. Docket 1690; Order Granting Fourth
Omnibus Objection of Carmin Reiss, in her Capacity as Trustee of the Insys Victims Restitution Trust. Docket 1691;
Order Granting Fifth Omnibus Objection of Carmin Reiss, in her Capacity as Trustee of the Insys Victims
Restitution Trust. Docket 1692.
843

Docket 1692.

844

Docket 1688; Docket 1689; Docket 1690; Docket 1691; Docket 1692.

845

Adversary Case 21-50140, Adversary Case 21-50141, Adversary Case 21-50142, Adversary Case 21-50143,
Adversary Case 21-50144, Adversary Case 21-50145, Adversary Case 21-50146, Adversary Case 21-50147,
Adversary Case 21-50148, Adversary Case 21-50149, Adversary Case 21-50150, Adversary Case 21-50151,
Adversary Case 21-50152, Adversary Case 21-50153, Adversary Case 21-50154, Adversary Case 21-50155,
Adversary Case 21-50156, Adversary Case 21-50157, Adversary Case 21-50158, Adversary Case 21-50159,
Adversary Case 21-50160, Adversary Case 21-50161, Adversary Case 21-50162, Adversary Case 21-50163,
Adversary Case 21-50164, Adversary Case 21-50165, Adversary Case 21-50166, Adversary Case 21-50167,
Adversary Case 21-50168, Adversary Case 21-50169, Adversary Case 21-50170, Adversary Case 21-50171,
Adversary Case 21-50172, Adversary Case 21-50173, Adversary Case 21-50174, Adversary Case 21-50175,
Adversary Case 21-50176, Adversary Case 21-50177, Adversary Case 21-50178, Adversary Case 21-50179,
Adversary Case 21-50180, Adversary Case 21-50181, Adversary Case 21-50182, Adversary Case 21-50183,
Adversary Case 21-50184, Adversary Case 21-50185, Adversary Case 21-50186, Adversary Case 21-50187,
Adversary Case 21-50188, Adversary Case 21-50189, Adversary Case 21-50190, Adversary Case 21-50191,
Adversary Case 21-501092, Adversary Case 21-50193, Adversary Case 21-50194, Adversary Case 21-50195,
Adversary Case 21-50196, Adversary Case 21-50320, Adversary Case 21-50321, Adversary Case 21-50330,
Adversary Case 21-50331, Adversary Case 21-50336, Adversary Case 21-50337, Adversary Case 21-50338,
Adversary Case 21-50339, Adversary Case 21-50340, Adversary Case 21-50341, Adversary Case 21-50343,
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on and during the 90 days immediately preceding the date of the filing of the petition,” meaning
the alleged transfers were made while Insys was presumed to be insolvent.846 Bankruptcy Code
section 547 provides that preferential transfers should be avoided and are recoverable by the
Liquidating Trustee pursuant to Bankruptcy Code section 550.847 However, it appears that the
majority of these claims were dismissed.848
On June 10, 2021, William Henrich brought four fraudulent transfer claims under
Bankruptcy Code section 548 for no less than $750,000 against Elizabeth Gurrieri, Jeffrey
Pearlman, Richard Simon, and John Kapoor.849 Every claim except that against John Kapoor was
dismissed.850 On April 27, 2022, the Court extended Kapoor’s time to answer to May 10, 2022.851
XI.

Professional Compensation

On May 1, 2020, the Court entered an omnibus order awarding final compensation for
Professional Fee Claims.852 The Court approved all final fee applications without reduction, listed
in the chart below:
Applicant

Role

Cooley LLP
Ernst & Young LLP
Rakoczy Molino Mazzochi Siwik LLP
Holland & Knight LLP
Weil, Gotshal, & Manges LLP
Richards, Layton & Finger, P.A.

Special Counsel to Insys
Accounting Services Provider to Insys
Lead Patent Litigation Counsel to Insys
Special Litigation Counsel to Insys
Counsel to Insys
Co-Counsel to Insys

Total Approved Fees
& Expenses
$471, 568.29
$26,452.50
$528,469.69
$534,826.90
$12,024,711.07
$2,830,780.90

Adversary Case 21-50344, Adversary Case 21-50345, Adversary Case 21-50346, Adversary Case 21-50347,
Adversary Case 21-50348, Adversary Case 21-50349, Adversary Case 21-50350, Adversary Case 21-50351,
Adversary Case 21-50352, Adversary Case 21-50353, Adversary Case 21-50354, Adversary Case 21-50355,
Adversary Case 21-50356, Adversary Case 21-50357, Adversary Case 21-50358, Adversary Case 21-50359,
Adversary Case 21-50360, Adversary Case 21-50361, Adversary Case 21-50362, Adversary Case 21-50363.
846

Citing 11 U.S.C. § 547(f).

847

Citing 11 U.S.C. 547 and 11 U.S.C. 550.

849

Adversary case 21-50556; Adversary case 21-50558; Adversary case 21-50559

850

Adversary case 21-50556, Docket 11; Adversary case 21-50558, Docket 5; Adversary case 21-50559, Docket 3.

851

Adversary case 21-50557, Motion of Debtors Pursuant to 11 U.S.C. §§ 105(a) and 521(a) and Fed. R. Bankr. P
1007 for Entry of Order Extending Time to File Schedules of Assets and Liabilities and Statements of Financial
Affairs. Docket 26.
852

Omnibus Order Awarding Final Allowance of Compensation for Services Rendered and Reimbursement of
Expenses. Docket 1336.

105

Wilson, Sonsini, Goodrich & Rosati,
P.C.
Epiq Corporate Restructuring, LLC
Carlton Fields, P.A.
Bayard, P.A.
Akin, Gump, Strauss, Hauer & Feld,
LLP
Province, Inc.
FTI Consulting, Inc.
Lazard Frères & Co. LLC

Special Litigation Counsel to Insys

$752,406.01

Administrative Advisor to Insys
Special Counsel to Insys
Co-Counsel to the Creditors’ Committee
Counsel to the Creditors’ Committee

$139,806.88
$792,390.97
$777,574.33
$5,602,691.75

Financial Advisor to the Creditors’ Committee
Financial Advisor to Insys
Investment Banker to Insys

$2,895,215.50
$5,256,149.27
$4,114,524.06

TOTAL

XII.

$36,747,568.10

Current Status

While Insys went through most of the chapter 11 bankruptcy proceedings, the Adversary
Proceedings continue today, and the objections deadline for all claims was extended to January
28, 2023.853 Insys paid some Professional Fee Claims, and as of May 16, 2022, had paid
$21,418,420.854 As stated previously, many of Insys’s patents and patent applications were to
expire in the next coming years, and due to the fraudulent schemes to the Insys’s downfall, it is
likely that this is the end for Insys Therapeutics, Inc.855

853

Motion of the Liquidating Trustee of the Insys Liquidating Trust for Entry of an Order Extending the Time to
Object to All Claims. Docket 1772 at 1.
854

Chapter 11 Post-Confirmation Report for the Quarter Ending: 12/31/21 filed by ILT. Docket 1822 at 2.

855

See III. b. Products for more.
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XIII.

Appendix of Defined Terms

Adequate Assurance: allows a contract party with reasonable grounds to believe that its
counterparty will be unable to perform, to demand that the counterparty provide “adequate
assurances” that the counterparty will perform its contractual obligations. (Adequate Assurance).
Administrative Expense Claims: any Claim for costs and expenses of administration of the
Chapter 11 Cases pursuant to sections 327, 328, 330, 365, 503(b), 507(a)(2), or 507(b) of the
Bankruptcy Code, including (i) the actual and necessary costs and expenses incurred on or after
the Petition Date and through the Effective Date of preserving the Estates and operating the
Debtors’ business, (ii) Professional Fee Claims, (iii) all fees and charges assessed against the
Estates pursuant to sections 1911 through 1930 of chapter 123 of title 28 of the United States Code,
(iv) all Allowed Claims that are to be treated as Administrative Expense Claims pursuant to a Final
Order of the Bankruptcy Court under section 546(c)(2) of the Bankruptcy Code, and (v) Cure
Claims.
Allowed: with respect to any Claim against or Interest in a Debtor, any Claim or Interest (i) the
amount of which has been agreed by, as applicable, the Debtors, the Liquidating Debtors, the
Liquidating Trustee, the ILT Claims Arbiter, or the VRT Claims Administrator, (ii) that has been
determined by Final Order of a court of competent jurisdiction, which may include the Bankruptcy
Court, (iii) that is compromised, settled, or otherwise resolved after the Effective Date pursuant to
the authority of the Debtors, the Liquidating Debtors, the Liquidating Trustee, the ILT Claims
Arbiter, or the VRT Claims Administrator, as applicable, (iv) that is listed in the Schedules as
liquidated, non-contingent, and undisputed, (v) arising on or before the Effective Date as to which
no objection to allowance has been interposed within the time period set forth in the Plan, and (vi)
that is expressly allowed hereunder; provided, however, that the Liquidating Debtors and the
Liquidating Trustee shall retain all Claims and defenses with respect to Allowed Claims that are
reinstated or otherwise Unimpaired pursuant to this Plan.
Authorized Acts: those actions that the Liquidating Trustee (through the Trusts, Debtors, the
Liquidating Debtors, or otherwise) is authorized to perform in accordance with the applicable Trust
Agreement including, but not limited to: (i) wind down, dissolve, and liquidate the Liquidating
Debtors and their Estates and the Trust Assets; (ii) prosecute and liquidate Causes of Action, other
than those released pursuant to Section 10.5(a) of this Plan; (iii) collect and administer all
consideration to be provided to the Debtors or the Liquidating Debtors under the Subsys Asset
Purchase Agreement; (iv) if applicable, continue limited operations of the Liquidating Debtors
during the Operating Term to the extent reasonably necessary, in the discretion of the Liquidating
Trustee, and subject to the approval of the ILT Board, to maximize value; (v) administer, process,
settle, resolve, liquidate, satisfy, and pay (from the designated funds therefor), as applicable,
Claims against the Debtors; (vi) maintain, administer, and make Distributions from the Priority
Reserve to satisfy Allowed (a) Administrative Expense Claims,(b) Secured Claims, and (c) Priority
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Claims; (vii) maintain, administer, and make Distributions from the Trust Operating Reserves to
satisfy Trust Operating Expenses; (viii) maintain, administer, and make distributions from the
Disputed Claims Reserves to the Recovery Funds; (ix) maintain, administer, and make
Distributions from the Recovery Funds to holders of Allowed General Unsecured Claims as set
forth in this Plan; (x) upon expiration of the Operating Term, liquidate all Remaining Assets and
make any final Distributions pursuant to Section 6.14 of this Plan;(xi) administer the closing of
the Chapter 11 Cases in accordance with the Bankruptcy Code and the Bankruptcy Rules; (xii) (a)
obtain all of the Debtors’ and the Liquidating Debtors’ documents, books, and records, (b) retain
such documents, books, and records subject to the Debtors’ obligations with respect to record
retention existing as of the Effective Date, and (c) in consultation with the ILT Board and
considering all factors, make determinations with regard to the use of such documents, books, and
records; provided, however, that (1) any such use will be in a manner that reasonably protects
against disclosure of personally identifiable information and that complies with all applicable laws,
including HIPAA, and, in the absence of modification, any confidentiality agreements, protective
orders, or other similar obligations regarding the use of the Debtors’ and the Liquidating Debtors’
documents, books, and records, and (2) the publication of any such documents, books, and records
required by Section 5.6(g) of this Plan will be governed by that section of the Plan; and (xiii) carry
out the purposes and obligations of the Trusts as set forth in the Trust Agreements.
Bar Date Order: Counterparties to any such contracts, engagement letters, retention agreements,
and similar arrangements were required to file proofs of claim by the General Bar Date.
Case Protocol: a document with a schedule and a potential path forward to resolve issues regarding
claim estimation, plan classification, allocations, and related issues.
Category 1 Distributions: Distributions of the first $3 million of Estate Distributable Value from
the ILT Recovery Fund on account of Allowed Claims, which shall be made only on account of
Allowed Trade and Other Unsecured Claims. Category 1 Distributions shall be made in accordance
with reallocations resulting from the DOJ Distribution Reallocation.
Category 2 Distributions: (i) with respect to Distributions of the next $35 million of Estate
Distributable Value following the Distribution of $3 million in Category 1 Distributions to holders
of Allowed Trade and Other Unsecured Claims, fifty-five percent (55%) of the Estate Distributable
Value composing such Distributions and (ii) with respect to Distributions after $38 million of
Estate Distributable Value has been distributed on account of Allowed Non-PI General Unsecured
Claims in the aggregate, twenty percent (20%) of the incremental Estate Distributable Value
composing such Distributions. Category 2 Distributions shall be made in accordance with
reallocations resulting from the DOJ Distribution Reallocation.
Category 3 Distributions: (i) with respect to Distributions of the next $35 million of Estate
Distributable Value following the payment of $3 million in Category 1 Distributions to holders of
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Allowed Trade and Other Unsecured Claims, forty-five percent (45%) of the Estate Distributable
Value composing such Distributions and (ii) with respect to Distributions after $38 million of
Estate Distributable Value has been distributed on account of Allowed Non-PI General Unsecured
Claims in the aggregate, eighty percent (80%) of the incremental Estate Distributable Value
composing such Distributions. Category 3 Distributions shall be made in accordance with
reallocations resulting from the DOJ Distribution Reallocation.
Claims Dispute Deadline: December 20, 2019, the deadline for all interested parties to object to
claims for voting procedures.
Class Representative(s): refers to the representative appointed for each class of Insys’s Final Plan
for Liquidation.
Confirmation Date: date on which the Clerk of the Bankruptcy Court enters the Confirmation
Order.
Disputed Claims Reserves: collectively, the reserves to be established with respect to each Class
of General Unsecured Claims (which may be a single or collective reserve for one or more Classes
of Claims), each maintained and administered by the Liquidating Trustee, and each to be held for
the benefit of holders of subsequently Allowed Claims in the applicable Class for Distributions in
accordance with the procedure set forth in Article VII hereof. The Disputed Claims Reserves with
respect to Disputed Non-PI General Unsecured Claims shall be held by the Insys Liquidation Trust
and the Disputed Claims Reserve with respect to Disputed Personal Injury Claims shall be held by
the Victims Restitution Trust and administered by the Liquidating Trustee. There shall also be
considered to be held in the Disputed Claims Reserves an undivided interest in the ILT Assets
allocable to Disputed Claims of such Class(es).
ERISA Health Plan Claimants: means, collectively, Pioneer Telephone Cooperative, Inc.
Employee Benefits Plan; Bios Companies, Inc. Welfare Plan; Pioneer Telephone Cooperative, Inc.
as Plan Sponsor and Fiduciary of Pioneer Telephone Cooperative, Inc. Employee Benefits Plan;
and Bios Companies, Inc. as Plan Sponsor and Fiduciary of Bios Companies, Inc. Welfare Plan
and all other private employer sponsored self-insured health plans subject to ERISA.
Estate Distributable Value: any available cash in the ILT Recovery Fund
GUC Recovery Reallocation Threshold: the point at which aggregate Distributions on account
of Non-PI General Unsecured Claims (including Distributions from the ILT Recovery Fund to
holders of Allowed Non-PI General Unsecured Claims and Distributions to Disputed Claims
Reserves for Disputed Non-PI General Unsecured Claims) is equal to or greater than $40.9 million.
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Insurance Ratepayers Class Claims: the Insurance Related Claims asserted against the Debtors
by one or more class representatives on behalf of the class of all individual holders of Insurance
Ratepayer Claims for the alleged increase in premium rates for such health insurance arising from
the Debtors’ acts or omissions leading to the improper payment of prescription drug costs for
Products of the Debtors.
Insurance Proceeds any proceeds recovered under the Insurance Policies, not including the
Products Liability Insurance Proceeds, for the Insys Liquidation Trust. Excess Products Liability
Insurance Proceeds means any Products Liability Insurance Proceeds held by the Victims
Restitution Trust after all Allowed Personal Injury Claims to have been satisfied in full.
ILT Claims Arbiter: the individual to be appointed pursuant to this Plan and the ILT Agreement
to determine the allocation of recoveries among holders of Allowed Claims within Class 4 and
Class 5, as necessary, if such Classes fail to agree with respect to such allocations prior to the
Effective Date. The identity of the ILT Claims Arbiter shall be disclosed as part of the Plan
Supplement, if the ILT Claims Arbiter has been selected by the time the Plan Supplement is filed.
For the avoidance of doubt, with respect to Class 4, the ILT Claims Arbiter will solely be
responsible for allocating aggregate recoveries between holders of Third Party Payor Claims, on
the one hand, and holders of Insurance Ratepayers Claims, on the other hand, and in Class 5, the
ILT Claims Arbiter will solely be responsible for allocating aggregate recoveries between the
holders of Hospital Claims, on the one hand, and the NAS Children, on the other.
ILT Recovery Fund: the fund established pursuant to this Plan to make Distributions on account
of Allowed Non-PI General Unsecured Claims, or as contemplated by agreement pursuant to
Section 4.8(c)(i) and funded periodically with Available Cash pursuant to Section 5.14 and Surplus
Reserved Cash pursuant to Section 5.15 of this Plan. The ILT Recovery Fund shall be held by the
Insys Liquidation Trust and administered by the Liquidating Trustee.; Priority Reserve means the
amount of Cash and Cash equivalents of the Debtors necessary to pay, if any: (i) Allowed
Administrative Expense Claims, (ii) Allowed Secured Claims, and (iii) Allowed Priority Claims,
to be reserved on the Effective Date. The amount to be placed in the Priority Reserve shall be
determined by Insys and the Creditors’ Committee, acting jointly. The Priority Reserve shall be
held by the Insys Liquidation Trust and administered by the Liquidating Trustee.
ILT Operating Expenses any and all costs, expenses, fees, taxes, disbursements, debts, or
obligations incurred from the operation and administration of the Insys Liquidation Trust,
including in connection with the reconciliation and administration of all Claims (other than
Personal Injury Claims), working capital, wind-down of the Liquidating Debtors and the
Remaining Assets and Causes of Action, recovery of Insurance Proceeds (other than Products
Liability Insurance Proceeds), and costs and fees of the Liquidating Trustee, the ILT Claims
Arbiter, the ILT Board, and any other professionals retained by the Insys Liquidation Trust. In the
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first instance, the ILT Operating Expenses are to be satisfied and paid from the ILT Operating
Reserve.
ILT Operating Reserve Cash in an amount estimated to be necessary to fund the ILT Operating
Expenses, which shall be held in a separate account established by the Liquidating Trustee.
Non-General Unsecured Claims: means any General Unsecured Claim other than any Claim in
Class 8 (Personal Injury Claims).
Non-Voting Classes: Either unimpaired or subordinated claims unaffected by the Final Plan.
Periodic Distribution Date means “periodically as determined by the Liquidating Trustee in its
reasonable discretion but, unless otherwise ordered by the Court, (i) the first Periodic Distribution
Date shall be no later than the first Business Day that is 180 days after the Initial Distribution Date,
(ii) until the second anniversary of the Effective Date, every subsequent Periodic Distribution Date
shall be no later than the date that is the first Business Day 180 days after the immediately
preceding Periodic Distribution Date, and (iii) after the second anniversary of the Effective Date,
every subsequent Periodic Distribution Date shall be no later than the first Business Day that is
365 days after the immediately preceding Periodic Distribution Date; provided, however, that the
timing of periodic distribution under this definition is subject to the terms of the Trust
Agreements.”
Plan Distribution Formula: applicable Class Formula Amount divided by the sum of all Class
Formula Amounts,” with respect to a particular Class.
Preference and Indemnity Proceeds: the amount of any value recovered from the prosecution or
settlement by the Liquidating Trustee of any and all actual or potential Claims or Causes of Action
to (i) avoid a transfer of property or an obligation incurred by any of the Debtors pursuant to any
applicable section of the Bankruptcy Code, including sections 502(d), 544, 545, 547, 548, 549,
550, 551, 553(b), and 724(a) of the Bankruptcy Code, or under similar or related state or federal
statutes and common law or (ii) recover on theories of contribution or indemnity under state or
federal statues, contract law, and common law, if the recovery of such amounts results in a Claim
against the Debtors held by the party from which the recovery of value was obtained. Any
Preference and Indemnification Proceeds not designated for Distribution to holders of Allowed
Trade and Other Unsecured Claims pursuant to Sections 4.3(a) and 6.2(d) of this Plan shall be
allocated to the ILT Recovery Fund and be deemed to be Estate Distributable Value for the benefit
of holders of Allowed Non-PI General Unsecured Claims.
Private Group Plan Distribution Percentage: with respect to a particular Class, the applicable
Private Group Formula Amount divided by the sum of the Private Group Formula Amounts.
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Priority Reserves: the amount of Cash and Cash equivalents of the Debtors necessary to pay, if
any, (i) Administrative Expense Claims, (ii) Secured Claims, and (iii) Priority Claims, to be
reserved on the Effective Date. The amount to be placed in the Priority Reserve shall be determined
by the Debtors and the Creditors’ Committee, acting jointly. The Priority Reserve shall be held by
the Insys Liquidation Trust and administered by the Liquidating Trustee.
Pro Rata Share: means allocated in accordance with the proportion that an Allowed Claim bears
to the aggregate amount of Allowed Claims and Disputed Claims within the same Class as such
Claim.
Product Liability Insurance Rights: any and all rights, titles, privileges, interests, claims,
demands, or entitlements of the Debtors to any proceeds, payments, benefits, Causes of Action,
choses in action, defense or indemnity arising under, or attributable to, any and all Products
Liability Insurance Policies, now existing or hereafter arising, accrued or unaccrued, liquidated or
unliquidated, matured or unmatured, disputed or undisputed, fixed, or contingent.
Professional Fee Claims: a Claim for professional services rendered, or costs incurred, on or after
the Petition Date and on or prior to the Effective Date by Professional Persons that is unpaid as of
the Effective Date, less any existing amounts held in escrow as security by a Professional Person
that such Professional Person is authorized to use to satisfy Allowed Professional Fee Claims
pursuant to the Interim Compensation Order.
Professional Fee Escrow Account: an interest-bearing account in an amount equal to the total
estimated amount of Professional Fee Claims and funded by the Debtors on the Effective Date.
Public Group Plan Distribution Percentage: (i) for Class 7, the DOJ Class Amount, and (ii) for
Class 8(a) and Class 8(b), collectively, $597 million.
Third Party Payor Claim: any Claim against the Debtors by health insurers, employer-provided
health care plans (including ERISA Health Plan Claims), union health and welfare funds, and all
other private providers of health care benefits, and any third party administrator or agents on their
behalf, arising from the Debtors’ acts or omissions leading to the improper payment of prescription
drug costs for Products of the Debtors, including the Third Party Payor Class Claim
Third Party Release: provides for releases for the Released Parties by a) the holders of all Claims
who vote to accept the Plan, (b) the holders of all Claims that are Unimpaired under the Plan, (c)
the holders of all Claims whose vote to accept or reject the Plan is solicited but who (i) do not vote
either to accept or to reject the Plan and (ii) do not opt out of granting the releases set forth in the
Plan, (d) the holders of all Claims or Interests who vote, or are deemed, to reject the Plan but do
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not opt out of granting the releases set forth in the Plan, and (e) all other holders of Claims and
Interests to the maximum extent permitted by law.
Trust Operating Expenses: collectively, the ILT Operating Expenses and the VRT Operating
Expenses.
Trust Operating Reserves: collectively, the ILT Operating Reserve and the VRT Operating
Reserve. The Trust Operating Reserves shall be administered by the Liquidating Trustee.
Trust Formation Transactions: means one or more transactions pursuant to section 1123(a)(5)(D)
of the Bankruptcy Code, including any transactions that may be necessary or appropriate to
effectuate the actions described in Sections 5.4 through 5.9 of this Plan, which include (i) the
establishment of the Trusts, (ii) the issuance and vesting of the Parent Equity Interest in the Parent
Holding Trust, (iii) the assignment and vesting of the ILT Assets in the Insys Liquidation Trust,
(iv) the assignment and vesting of the VRT Assets in the Victims Restitution Trust, (iv) the creation
of the Recovery Funds to make Distributions to holders of Allowed Claims, (v) the creation of the
Trust Operating Reserves to satisfy and pay Trust Operating Expenses, and (vi) the execution of
the Trust Transfer Agreement(s). The Debtors, the Liquidating Debtors, and the Liquidating
Trustee may take all actions consistent with this Plan and the Trust Agreements as may be
necessary or appropriate to affect the Trust Formation Transactions.
VRT Agreement the trust agreement establishing and delineating the terms and conditions for the
creation and operation of the Victims Restitution Trust, as it may be amended from time to time.
The VRT Agreement shall be filed with the Plan Supplement and shall be in form and substance
reasonably acceptable to the Creditors’ Committee.
VRT Claims Administrator: the individual to be appointed pursuant to the Plan and the VRT
Agreement to administer, dispute, object to, compromise, or otherwise resolve Personal Injury
Claims subject to the terms of this Plan. The identity of the VRT Claims Administrator shall be
disclosed as part of the Plan Supplement, if the VRT Claims Administrator has been selected by
the time the Plan Supplement is filed.
VRT Insurance Negotiator: means the individual that may be appointed pursuant to this Plan and
the VRT Agreement to negotiate with and, if necessary, litigate against the Products Liability
Insurance Companies to recover Products Liability Insurance Proceeds for the benefit of holders
of Allowed Personal Injury Claims and Allowed SMT Group Claims. ILT Insurance Negotiator
means the individual as defined in Section 5.8 of this Plan.
VRT Operating Reserve: The VRT Operating Reserve was established by the Liquidating Trustee
and meant the Cash in an amount estimated to be necessary to fund the VRT Operating Expenses
in accordance with Section 5.9(d) of this Plan, which shall be held in a separate account established
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by the Liquidating Trustee. The VRT Operating Reserve is to be reserved in a segregated account
on the Effective Date or as soon as practicable thereafter from the Debtors’ Cash and Cash
equivalents in the amount of $[1 million].856

856

Docket 612; Docket 894; Docket 955.
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